Rank;Title;Status;Conditions;Interventions;CAR_target;Phases;URL
1;Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas;Recruiting;Glioma|Malignant Glioma of Brain|Recurrence Tumor;Biological: chimeric antigen receptor T cells;EGFRvIII|IL13Ralpha2|HER2|CD133|EphA2|GD2;Phase 1;https://ClinicalTrials.gov/show/NCT03423992
2;Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia;Unknown status;Recurrent B-Cell Tumor|Refractory B-Cell Tumor;Biological: CD19-specific chimeric antigen receptor;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02644655
3;Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted Œ≥Œ¥ T Cells for Relapsed or Refractory Solid Tumour;Not yet recruiting;Colorectal Cancer|Triple Negative Breast Cancer|Sarcoma|Nasopharyngeal Carcinoma|Prostate Cancer|Gastric Cancer;Biological: Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell;NKG2DL;Phase 1;https://ClinicalTrials.gov/show/NCT04107142
4;A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma;Active, not recruiting;Multiple Myeloma;Biological: LCAR-B38M CAR-T Cell;BCMA;Phase 2;https://ClinicalTrials.gov/show/NCT03758417
5;Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.;Recruiting;Advanced Solid Tumor;Drug: CAR-CLDN18.2 T-Cells;claudin18.2;Phase 1;https://ClinicalTrials.gov/show/NCT03874897
6;Anti-CD19, Dual Co-stimulatory (4-1BB, CD3Œ∂) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL);Not yet recruiting;Relapsed Non Hodgkin Lymphoma|Relapsed Adult ALL|Relapsed Pediatric ALL;Biological: autologous CD19-directed chimeric antigen receptor (CAR) T-cells;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03938987
7;Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies;Recruiting;B Acute Lymphoblastic Leukemia|CD19 Positive|Minimal Residual Disease|Philadelphia Chromosome Positive|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia;Biological: Chimeric Antigen Receptor T-Cell Therapy|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Other: Questionnaire Administration;CD19-CD22;Phase 1;https://ClinicalTrials.gov/show/NCT03241940
8;Chimeric Antigen Receptor T Cells Targeting Glypican-3;Recruiting;Hepatocellular Carcinoma;Biological: CAR-GPC3 T Cells;GPC3;Phase 1;https://ClinicalTrials.gov/show/NCT03884751
9;T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors;Recruiting;Brain Tumor, Recurrent|Brain Tumor, Refractory;Biological: HER2-specific T cells;HER2;Phase 1;https://ClinicalTrials.gov/show/NCT02442297
10;CD19/CD22 Chimeric Antigen Receptor(CAR) T Cells in Adults With Recurrent/Refractory B Cell Malignancies;Recruiting;B Acute Lymphoblastic Leukemia|CD19 Positive|Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma of the Elderly|Minimal Residual Disease|Philadelphia Chromosome Positive|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma;Biological: Chimeric Antigen Receptor T-Cell Therapy|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Other: Questionnaire Administration;CD19-CD22;Phase 1;https://ClinicalTrials.gov/show/NCT03233854
11;Study of CXCR5 Modified EGFE Chimeric Antigen Receptor Autologous T Cells in EGFR- Positive Patients With Advanced Non-small Cell Lung Cancer;Recruiting;Non Small Cell Lung Cancer;Biological: CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells;EGFR;Phase 1;https://ClinicalTrials.gov/show/NCT04153799
12;AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma;Recruiting;Non-Hodgkin Lymphoma;Drug: Cyclophosphamide|Drug: Fludarabine|Biological: CAR-T Cells;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03434769
13;CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma;Recruiting;Lymphoma;Biological: CD19 targeted chimeric antigen receptor T cells;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03118180
14;Anti-CD19:TCRŒ∂ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma;Not yet recruiting;Lymphoma, B Cell;Biological: IL-2 pre-treated CD19 cells|Biological: IL-7/IL-15 pre-treated CD19 cells;CD19;Phase 4;https://ClinicalTrials.gov/show/NCT02992834
15;CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study;Not yet recruiting;T Lymphoblastic Leukemia/Lymphoma|Extramedullary NK-T-cell Lymphoma, Nasal Type|Peripheral T-cell Lymphoma, Nonspecific|Angioimmunoblastic T-cell Lymphoma|Enteropathy-Associated T-Cell Lymphoma|Anaplastic Large Cell Lymphoma, ALK-negative|T-cell Lymphoblastic Leukemia;Biological: T cell injection targeting CD7 chimeric antigen receptor;CD7;Phase 1;https://ClinicalTrials.gov/show/NCT04480788
16;A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma;Recruiting;Leukemia|Lymphoma;Biological: Chimeric Antigen Receptor Modified T cells Targeting CD19;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02349698
17;Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma;Recruiting;Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma|Progressive Disease|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent High Grade B-Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory High Grade B-Cell Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma;Biological: Anakinra|Biological: Axicabtagene Ciloleucel|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Fludarabine Phosphate;CD19;Phase 2;https://ClinicalTrials.gov/show/NCT04205838
18;Production of Clinical-grade Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory B-cell Malignancies;Recruiting;Leukemia;Other: peripheral blood;CD19;;https://ClinicalTrials.gov/show/NCT03624686
19;Study of Sequential CAR-T Cell Treating Leukemia Children;Recruiting;Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia, in Relapse|Refractory Acute Lymphoid Leukemia;Biological: chimeric antigen receptor T cell;CD19|CD22;Phase 2;https://ClinicalTrials.gov/show/NCT04340154
20;T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies;Active, not recruiting;Lymphoma, B-Cell|Lymphoma, Non-hodgkins;Biological: Anti-CD19-CAR T cells|Drug: Cyclophosphamide|Drug: Fludarabine;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT02659943
22;CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS;Recruiting;Leukemia, Acute Lymphocytic (ALL)|Leukemia, Acute Myelogenous (AML)|Myelodysplastic Syndromes;Biological: Chimeric antigen receptor T cells|Biological: peptide specific dendritic cell;CD19|CD20|CD22|CD10|CD33|CD38|CD56|CD117|CD123|CD34|Muc1;Phase 1;https://ClinicalTrials.gov/show/NCT03291444
24;A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy;Unknown status;Carcinoma, Hepatocellular|Pancreatic Cancer Metastatic|Colorectal Cancer Metastatic;Drug: CAR-T cell;GPC3|CEA|Mesothelin;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02959151
26;ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy);Recruiting;Lymphomas Non-Hodgkin's B-Cell|Diffuse Large B-cell Lymphoma (DLBCL)|Primary Mediastinal B-cell Lymphoma (PMBCL)|Transformed Follicular Lymphoma (TFL)|Follicular Lymphoma (FL)|Mantle Cell Lymphoma (MCL);Biological: WZTL002-1 (1928T2z CAR-T cells)|Drug: Cyclophosphamide and Fludarabine lymphodepleting chemotherapy;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT04049513
27;Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma;Not yet recruiting;Lymphoma;Biological: The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T);CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03086954
28;Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.;Unknown status;Pancreatic Cancer|CAR;Drug: Chimeric antigen receptor T cell;Mesothelin|PSCA|CEA|HER2|MUC1|EGFRvIII;Early Phase 1;https://ClinicalTrials.gov/show/NCT03267173
29;Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma;Recruiting;Mantle Cell Lymphoma|Follicular Lymphoma|Splenic Marginal Zone Lymphoma|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Nodal Marginal Zone Lymphoma|Indolent Non-hodgkin Lymphoma;Drug: CAR.k.28|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Bendamustine;Kappa;Phase 1;https://ClinicalTrials.gov/show/NCT04223765
30;Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma;Completed;ALL|B Cell Lymphoma|Leukemia|Large Cell Lymphoma|Non-Hodgkin Lymphoma;Biological: Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR);CD19;Phase 1;https://ClinicalTrials.gov/show/NCT01593696
31;CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma;Unknown status;Acute Myeloid Leukemia|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|T-cell Prolymphocytic Leukemia|T-cell Large Granular Lymphocytic Leukemia|Peripheral T-cell Lymphoma, NOS|Angioimmunoblastic T-cell Lymphoma|Extranodal NK/T-cell Lymphoma, Nasal Type|Enteropathy-type Intestinal T-cell Lymphoma|Hepatosplenic T-cell Lymphoma;Biological: anti-CD7 CAR-pNK cells;CD7;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02742727
32;Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen;Recruiting;Acute Myeloid Leukemia;Biological: CLL-1.CAR T cells;CLEC12A;Phase 1;https://ClinicalTrials.gov/show/NCT04219163
33;Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MPP2+ Recurrent or Progressive Glioblastoma;Recruiting;Recurrent Glioblastoma|Recurrent Malignant Glioma|Recurrent WHO Grade II Glioma|Recurrent WHO Grade III Glioma;Biological: Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes;Chlorotoxin;Phase 1;https://ClinicalTrials.gov/show/NCT04214392
34;3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA;Withdrawn;Neuroblastoma;Drug: cyclophosphamide|Drug: Fludarabine|Genetic: GINAKIT Cells;GD2;Phase 1;https://ClinicalTrials.gov/show/NCT02439788
35;Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma;Not yet recruiting;CD19 Positive|CD22 Positive|Minimal Residual Disease|Progressive Disease|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Non-Hodgkin Lymphoma|Refractory B Acute Lymphoblastic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Non-Hodgkin Lymphoma;Biological: Autologous CD19/CD22 Chimeric Antigen Receptor T-cells|Drug: Cyclophosphamide|Drug: Fludarabine;CD19-CD22;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT04029038
36;C-CAR011 Treatment in Subjects With ALL After HSCT;Active, not recruiting;Acute Lymphoblastic Leukemia(ALL);Biological: C-CAR011;CD19;Not Applicable;https://ClinicalTrials.gov/show/NCT03327285
37;4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3;Recruiting;Advanced Hepatocellular Carcinoma;Drug: CAR-GPC3 T Cells;GPC3;Phase 1;https://ClinicalTrials.gov/show/NCT03980288
38;Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma;Recruiting;Refractory Non-Hodgkin Lymphoma|Burkitt Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Primary Mediastinal Large B Cell Lymphoma|Diffuse Large B Cell Lymphoma|Small Lymphocytic Lymphoma|Transformed Lymphoma;Drug: Fludarabine|Drug: Cyclophosphamide|Biological: anti-CD19 CAR-T cells;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT04545762
39;CD38-targeted Chimeric Antigen Receptor T Cell (CART) in Relapesd or Refractory Acute Myeloid Leukemia;Recruiting;Acute Myeloid Leukemia;Biological: CART-38;CD38;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT04351022
40;A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma;Recruiting;Lymphoma Non-Hodgkin|Agressive Lymphoma|Diffuse-large B-cell Lymphoma (DLBCL);Biological: CC-97540;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT04231747
41;Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma;Not yet recruiting;Relapsed and Refractory|Lymphoid Hematological Malignancies;Drug: GC022F CAR-T cells;CD19-CD22;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT04626908
42;Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies;Recruiting;Leukemia, B-Cell|Lymphoma, B-Cell;Biological: CD19CART;CD19;Not Applicable;https://ClinicalTrials.gov/show/NCT02813837
44;CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas;Recruiting;Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma;Biological: CART30;CD30;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02259556
45;A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors;Completed;Sarcoma|Osteosarcoma|Neuroblastoma|Melanoma;Biological: Anti-GD2-CAR engineered T cells|Drug: AP1903|Drug: Cyclophosphamide;GD2;Phase 1;https://ClinicalTrials.gov/show/NCT02107963
47;Claudin18.2 CAR-T (CT041) in Patients With Gastric or Pancreatic Cancer;Recruiting;Gastric Cancer|Pancreatic Cancer;Biological: CT041;Claudin18.2;Phase 1;https://ClinicalTrials.gov/show/NCT04404595
48;Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation;Recruiting;Leukemia, B-cell|Lymphoma, Hodgkins|Lymphoma, Non-hodgkins|Lymphoma, B-Cell;Procedure: Allogeneic stem cell transplant|Biological: Anti-CDl9-chimeric- antigen-receptor- transduced T cells|Procedure: Leukapheresis;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT01087294
49;A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma;Recruiting;Multiple Myeloma;Biological: CC-98633;BCMA;Phase 1;https://ClinicalTrials.gov/show/NCT04394650
50;CD4CAR for CD4+ Leukemia and Lymphoma;Recruiting;T-cell Lymphoma|T-cell Leukemia;Biological: CD4CAR;CD4;Phase 1;https://ClinicalTrials.gov/show/NCT03829540
51;Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies;Unknown status;Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Lymphoma;Combination Product: Drugs and Anti-CD19-CAR transduced T cells;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03076437
52;Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma;Terminated;Patients With Residual or Reccurent EGFRvIII+ Glioma;Biological: CART-EGFRvIII T cells;EGFRvIII;Phase 1;https://ClinicalTrials.gov/show/NCT02209376
53;Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia;Recruiting;Acute Myelogenous Leukemia;Biological: CD33CART;CD33;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03971799
54;Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands;Completed;Acute Myeloid Leukemia|Myelodysplastic Syndrome|Multiple Myeloma;Biological: CM-CS1 T-cell infusion;NKG2D;Phase 1;https://ClinicalTrials.gov/show/NCT02203825
55;Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia;Terminated;Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia;Biological: CART22 cells;CD22;Phase 1;https://ClinicalTrials.gov/show/NCT02588456
56;MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma;Recruiting;Multiple Myeloma;Biological: Infusion of MCARH109 T cells;GPRC5D;Phase 1;https://ClinicalTrials.gov/show/NCT04555551
57;Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia;Unknown status;Acute Lymphoblastic Leukemia;Biological: Third generation CAR-T cells;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT02186860
58;Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR);Recruiting;Hepatocellular Carcinoma;Genetic: GLYCAR T cells|Drug: Cytoxan|Drug: Fludarabine;GPC3;Phase 1;https://ClinicalTrials.gov/show/NCT02905188
59;Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors;Not yet recruiting;Liver Cancer|Rhabdomyosarcoma|Malignant Rhabdoid Tumor|Liposarcoma|Wilms Tumor|Yolk Sac Tumor;Genetic: AGAR T cells|Drug: Cytoxan|Drug: Fludara;GPC3;Phase 1;https://ClinicalTrials.gov/show/NCT04377932
60;Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP);Recruiting;Liver Cancer;Genetic: GAP T cells|Drug: Cytoxan|Drug: Fludara;GPC3;Phase 1;https://ClinicalTrials.gov/show/NCT02932956
61;Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies;Unknown status;Chronic Lymphocytic Leukemia|Acute Lymphocytic Leukemia|Lymphoma;Drug: Fludarabine|Drug: Cyclophosphamide|Biological: Anti-CD19-CAR transduced T cells;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT02456350
62;Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children;Recruiting;Acute Lymphoblastic Leukemia, Pediatric|Acute Lymphoblastic Leukemia, in Relapse|Refractory Acute Lymphoblastic Leukemia;Biological: Murine autologous anti-CD19 chimeric antigen receptor T cells;CD19;Phase 2;https://ClinicalTrials.gov/show/NCT04325841
63;T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR);Withdrawn;Hepatocellular Carcinoma|Hepatoblastoma;Genetic: TEGAR T cells|Drug: Cytoxan|Drug: Fludarabine;GPC3;Phase 1;https://ClinicalTrials.gov/show/NCT04093648
64;Study of Anti-CD22 CAR-T Cells Treating Leukemia Children;Recruiting;Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia, in Relapse|Refractory Acute Lymphoblastic Leukemia;Biological: Autologous humanized anti-CD22 chimeric antigen receptor T cells;CD22;Phase 2;https://ClinicalTrials.gov/show/NCT04340167
65;Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MM;Recruiting;Multiple Myeloma;Biological: Targeting CD269 chimeric antigen receptor engineered T cells;BCMA;Phase 1;https://ClinicalTrials.gov/show/NCT04500431
67;A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma;Active, not recruiting;Multiple Myeloma;Biological: JNJ-68284528;BCMA;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03548207
68;A Clinical Study on the Safety and Efficacy of CAR-T Therapy for the TM4SF1- and EpCAM-positive Solid Tumors;Not yet recruiting;Advanced Solid Tumor|Neoplasms;Biological: TM4SF1- and EpCAM-positive chimeric antigen receptor T-cell therapy;TM4SF1|EpCAM;Not Applicable;https://ClinicalTrials.gov/show/NCT04151186
69;Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors;Active, not recruiting;B Cell Lymphoma|B Cell Leukemia|Myeloma|Hepatocellular Carcinoma|Pancreatic Carcinoma|Adenocarcinoma of Esophagogastric Junction;Genetic: CAR-CD19 T cell|Genetic: CAR-BCMA T cell|Genetic: CAR-GPC3 T cell|Genetic: CAR-CLD18 T cell|Drug: Fludarabine|Drug: Cyclophosphamide;CD19|BCMA|GPC3|claudin18.2;Not Applicable;https://ClinicalTrials.gov/show/NCT03302403
70;3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN;Active, not recruiting;Neuroblastoma;Genetic: iC9-GD2 T Cells - frozen|Genetic: iC9-GD2 T Cells - fresh|Drug: Cytoxan|Drug: Fludara|Drug: Keytruda|Genetic: iC9-GD2 T cells;GD2;Phase 1;https://ClinicalTrials.gov/show/NCT01822652
71;CAR-T Cell Immunotherapy for HCC Targeting GPC3;Withdrawn;GPC3 Positive Hepatocellular Carcinoma|CAR-T Cell Immunotherapy;Biological: CAR-T cell immunotherapy;GPC3;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02723942
72;HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases;Recruiting;Malignant Neoplasm|Metastatic Malignant Neoplasm in the Brain|Metastatic Malignant Neoplasm in the Leptomeninges|Breast Cancer|HER2-positive Breast Cancer;Biological: Chimeric Antigen Receptor T-Cell Therapy;Her2;Phase 1;https://ClinicalTrials.gov/show/NCT03696030
73;Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma;Active, not recruiting;Sarcoma;Genetic: Autologous HER2-specific T cells|Drug: Fludarabine|Drug: Cyclophosphamide|Genetic: Autologous CAR Positive T cells;Her2;Phase 1;https://ClinicalTrials.gov/show/NCT00902044
74;HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors;Recruiting;Central Nervous System Tumor, Pediatric|Glioma|Ependymoma|Medulloblastoma|Germ Cell Tumor|Atypical Teratoid/Rhabdoid Tumor|Primitive Neuroectodermal Tumor|Choroid Plexus Carcinoma|Pineoblastoma;Biological: HER2-specific chimeric antigen receptor (CAR) T cell;Her2;Phase 1;https://ClinicalTrials.gov/show/NCT03500991
75;Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy;Active, not recruiting;Leukemia|Lymphoma;Biological: Adult differentiated autologous T-cells;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03144583
76;CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor;Unknown status;Hepatocellular Carcinoma|Non-small Cell Lung Cancer|Pancreatic Carcinoma|Triple-Negative Invasive Breast Carcinoma|Malignant Glioma of Brain|Colorectal Carcinoma|Gastric Carcinoma;Biological: anti-MUC1 CAR-pNK cells;MUC1;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02839954
77;Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma;Recruiting;Multiple Myeloma;Biological: Descartes-08|Drug: Fludarabine|Drug: Cyclophosphamide;BCMA;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03448978
78;GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma;Recruiting;Neuroblastoma;Genetic: GINAKIT Cells|Drug: Cyclophosphamide|Drug: Fludarabine;GD2;Phase 1;https://ClinicalTrials.gov/show/NCT03294954
79;A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers;Recruiting;Non-Small Cell Lung Cancer|Ovarian Cancer|Fallopian Tube Cancer|Triple Negative Breast Cancer|Multiple Myeloma|Pancreatic Ductal Adenocarcinoma;Biological: CART-TnMUC1|Drug: Cyclophosphamide|Drug: Fludarabine;MUC1;Phase 1;https://ClinicalTrials.gov/show/NCT04025216
80;Chimeric Antigen Receptor-Modified T Cells for Breast Cancer;Withdrawn;Breast Cancer;Biological: HER-2-targeting CAR T Cells infusion;HER2;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02547961
81;A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas;Recruiting;CD20 Positive|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Lymphoplasmacytic Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Transformed Non-Hodgkin Lymphoma|Recurrent Transformed B-cell Non-Hodgkin Lymphoma|Recurrent Transformed Chronic Lymphocytic Leukemia|Refractory Marginal Zone Lymphoma|Refractory Transformed B-cell Non-Hodgkin Lymphoma|Refractory Transformed Chronic Lymphocytic Leukemia;Biological: Chimeric Antigen Receptor T-Cell Therapy|Drug: Cyclophosphamide|Drug: Fludarabine|Other: Laboratory Biomarker Analysis|Procedure: Leukapheresis|Drug: Fludarabine Phosphate;CD20;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03277729
82;Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL);Recruiting;Non Hodgkin Lymphoma;Biological: UCD19 CAR T Cells;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT04240808
83;CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.;Recruiting;Leukemia, B-cell;Biological: CART-19/22;CD19-CD22;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03614858
85;CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma;Recruiting;Lymphoma, Non-Hodgkin|Diffuse Large B Cell Lymphoma|Follicular Lymphoma;Biological: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells;CD19;Phase 2;https://ClinicalTrials.gov/show/NCT04089215
86;A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies;Recruiting;Diffuse Large B Cell Lymphoma|Follicular Lymphoma|Primary Cutaneous Follicle Centre Lymphoma|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Mantle Cell Lymphoma|Plasma Cell Neoplasm|B Cell Lymphoma;Drug: Autologous chimeric antigen receptor T cell transfusing agent targeting CD22;CD22;Phase 1;https://ClinicalTrials.gov/show/NCT03999697
88;CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies;Recruiting;B-Cell Acute Lymphoblastic Leukemia, Adult|B-cell Lymphoma Refractory|B-cell Lymphoma Recurrent;Drug: Fludarabine|Drug: Cyclophosphamide|Biological: CD19-CD34 CAR transduced T cells;CD19-CD34;Phase 1;https://ClinicalTrials.gov/show/NCT04214886
89;IL13Ralpha2-Targeted Chimeric Antigen Receptor (CAR) T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With Recurrent or Refractory Glioblastoma;Recruiting;Recurrent Glioblastoma|Refractory Glioblastoma;Biological: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells|Biological: Ipilimumab|Biological: Nivolumab|Other: Quality-of-Life Assessment|Other: Questionnaire Administration;IL13Ralpha2;Phase 1;https://ClinicalTrials.gov/show/NCT04003649
90;Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia;Recruiting;CD19 Positive|CD20 Positive|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Small Lymphocytic Lymphoma;Biological: Chimeric Antigen Receptor T-Cell Therapy|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Biological: Tocilizumab;CD19-CD20;Phase 1;https://ClinicalTrials.gov/show/NCT04007029
91;Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies;Recruiting;Acute Lymphoblastic Leukemia|B Cell Lymphoma;Genetic: Second generation humanized CAR-T cells;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT04008251
92;19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers;Recruiting;Diffuse Large B Cell Lymphoma|Primary Mediastinal Large B Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma|Chronic Lymphocytic Leukemia|Indolent Non-Hodgkin Lymphoma|Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia|Burkitt's Lymphoma|Primary CNS Lymphoma;Drug: 19(T2)28z1xx CAR T cells;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT04464200
93;CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies;Recruiting;Acute Lymphoblastic Leukemia|B Cell Lymphoma;Genetic: Second generation CAR-T cells;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02965092
94;Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma;Recruiting;Neuroblastoma|Effects of Immunotherapy;Biological: Anti-GD2 CART;GD2;Phase 1;https://ClinicalTrials.gov/show/NCT02765243
95;The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies;Recruiting;B Acute Lymphoblastic Leukemia|Mantle Cell Lymphoma|Follicular Lymphoma;Drug: CD19-CART;CD19;Early Phase 1;https://ClinicalTrials.gov/show/NCT04184414
96;Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN;Terminated;Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN);Biological: UCART123;CD123;Phase 1;https://ClinicalTrials.gov/show/NCT03203369
97;T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma;Suspended;Lymphoma, B-Cell|Lymphoma, Non-hodgkins|Chronic Lymphocytic Leukemia|B-Cell Chronic Lymphocytic Leukemia;Biological: Anti-CD19-CAR and Anti-CD20-CAR T cells|Drug: Cyclophosphamide|Drug: Fludarabine;CD19|CD20;Phase 1;https://ClinicalTrials.gov/show/NCT04160195
99;A Study of Anti-Lewis Y Chimeric Antigen Receptor-T Cells (LeY-CAR-T) in Patients With Solid Tumours;Active, not recruiting;Advanced Cancer;Biological: LeY CAR T cells;Lewis Y;Phase 1;https://ClinicalTrials.gov/show/NCT03851146
100;A Clinical Research of CAR T Cells Targeting CEA Positive Cancer;Unknown status;Lung Cancer|Colorectal Cancer|Gastric Cancer|Breast Cancer|Pancreatic Cancer;Biological: Anti-CEA-CAR T;CEA;Phase 1;https://ClinicalTrials.gov/show/NCT02349724
101;A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma;Recruiting;Multiple Myeloma;Drug: JNJ-68284528|Drug: Lenalidomide|Drug: Daratumumab|Drug: Bortezomib|Drug: Dexamethasone;BCMA;Phase 2;https://ClinicalTrials.gov/show/NCT04133636
102;CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies;Recruiting;Acute Lymphoid Leukemia|B-Cell Leukemia|Leukemia, Lymphocytic, B Cell|B-Cell Lymphoma|Lymphoma, Non-Hodgkin;Biological: CD19/CD22 CAR T-Cells|Drug: Fludarabine|Drug: Cyclophosphamide;CD19-CD22;Phase 1;https://ClinicalTrials.gov/show/NCT03448393
103;A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity;Recruiting;DLBCL|Neurotoxicity Syndromes;Drug: Defibrotide;CD19;Phase 2;https://ClinicalTrials.gov/show/NCT03954106
104;Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers;Recruiting;Pancreatic Cancer|Renal Cell Cancer|Breast Cancer|Melanoma|Ovarian Cancer;Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldesleukin|Biological: Anti-hCD70 CAR transduced PBL;CD70;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02830724
105;T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies;Recruiting;Acute Lymphoblastic Leukemia, B-precursor|Non-Hodgkin Lymphoma, B-cell;Biological: CD19 CAR T cells;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02772198
106;GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC;Recruiting;Hepatocellular Carcinoma;Biological: CAR-T cell immunotherapy;GPC3;Phase 1;https://ClinicalTrials.gov/show/NCT04121273
107;EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors;Recruiting;Central Nervous System Tumor, Pediatric|Glioma|Ependymoma|Medulloblastoma|Germ Cell Tumor|Atypical Teratoid/Rhabdoid Tumor|Primitive Neuroectodermal Tumor|Choroid Plexus Carcinoma|Pineoblastoma;Biological: EGFR806-specific chimeric antigen receptor (CAR) T cell;EGFR;Phase 1;https://ClinicalTrials.gov/show/NCT03638167
108;Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia;Terminated;Hematopoietic/Lymphoid Cancer|Acute Myeloid Leukemia;Procedure: Leukapheresis|Drug: Fludarabine|Drug: Cyclophosphamide|Biological: CD33-CAR-T Cell Infusion;CD33;Phase 1;https://ClinicalTrials.gov/show/NCT03126864
109;Autologous CARTmeso/19 Against Pancreatic Cancer;Unknown status;Pancreatic Cancer;Biological: CARTmeso CART19;CD19|Mesothelin;Early Phase 1;https://ClinicalTrials.gov/show/NCT03497819
110;CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients;Withdrawn;GD2 Positive Glioma|CAR-T Cell Immunotherapy;Biological: CAR-T cell immunotherapy;GD2;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03252171
111;Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL);Terminated;LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL);Biological: CART 19;CD19;Early Phase 1;https://ClinicalTrials.gov/show/NCT02640209
112;BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma;Recruiting;Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma;Biological: BCMA-specific CAR-expressing T Lymphocytes|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Gamma-Secretase Inhibitor LY3039478|Other: Laboratory Biomarker Analysis|Other: Pharmacokinetic Study;BCMA;Phase 1;https://ClinicalTrials.gov/show/NCT03502577
113;CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII;Completed;Malignant Glioma|Glioblastoma|Brain Cancer|Gliosarcoma;Biological: Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL|Drug: Aldesleukin|Drug: Fludarabine|Drug: Cyclophosphamide;EGFRvIII;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT01454596
114;A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALL;Unknown status;Relapsed or Refractory Acute Lymphoblastic Leukemia;Biological: C-CAR-011;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03018093
115;Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors;Recruiting;Central Nervous System Tumor|Diffuse Intrinsic Pontine Glioma|Diffuse Midline Glioma|Ependymoma|Medulloblastoma, Childhood|Germ Cell Tumor|Atypical Teratoid/Rhabdoid Tumor|Primitive Neuroectodermal Tumor|Choroid Plexus Carcinoma|Pineoblastoma, Childhood|Glioma;"Biological: SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel";B7H3;Phase 1;https://ClinicalTrials.gov/show/NCT04185038
116;CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients;Withdrawn;EphA2 Positive Malignant Glioma|CAR-T Cell Immunotherapy;Biological: CAR-T cell immunotherapy;EphA2;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02575261
117;Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children;Unknown status;Relapsed or Refractory Neuroblastoma;Biological: GD2-targeted CAR-T cells;GD2;Not Applicable;https://ClinicalTrials.gov/show/NCT02919046
118;High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma;Active, not recruiting;Non-Hodgkin's Lymphoma;Drug: Carmustine|Drug: Etoposide|Drug: Cytarabine|Drug: Melphalan|Biological: Pegfilgrastim|Biological: 19-28z T CELLS|Procedure: Autologous Stem Cell Transplantation;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT01840566
119;Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma;Active, not recruiting;Non Hodgkin Lymphoma;Biological: JWCAR029;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03355859
120;Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma;Active, not recruiting;Non Hodgkin Lymphoma;Biological: JWCAR029;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03344367
121;CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies;Active, not recruiting;Acute Biphenotypic Leukemia|Acute Lymphoblastic Leukemia|Blasts 5 Percent or More of Bone Marrow Nucleated Cells|CD19 Positive|Minimal Residual Disease|Non-Hodgkin Lymphoma|Small Lymphocytic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia;Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Biological: Tisagenlecleucel;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT02529813
122;Dose Optimization Trial of CD19 Redirected Autologous T Cells;Completed;Adult Patients Who Have Relapsed or Refractory CLL (3rd Line) or SLL;Biological: CART-19;CD19;Phase 2;https://ClinicalTrials.gov/show/NCT01747486
123;Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma;Recruiting;Multiple Myeloma;Biological: BCMA-CART cells;BCMA;Early Phase 1;https://ClinicalTrials.gov/show/NCT04186052
124;CAR-T Cell Therapy Targeting to CD19 for R/R ALL;Recruiting;Acute Lymphoblastic Leukemia With Failed Remission;Biological: CAR T-cell therapy;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03919240
125;Study of Safety and Efficacy of C-CAR011 in B-NHL Patients;Unknown status;Refractory or Relapsed Non-Hodgkin Lymphoma;Biological: C-CAR011;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03154775
126;A Phase‚Ö†b Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects;Completed;B-cell Non-Hodgkin Lymphoma;Biological: CD19-directed CAR-T cells;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03483688
127;CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML;Unknown status;Acute Myelogenous Leukemia|Acute Myeloid Leukemia|Acute Myeloid Leukemia With Maturation|Acute Myeloid Leukemia Without Maturation|ANLL;Biological: anti-CD33 CAR-NK cells;CD33;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02944162
128;EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast Cancer;Recruiting;Malignant Neoplasm of Nasopharynx TNM Staging Distant Metastasis (M)|Breast Cancer Recurrent;Biological: CAR-T cells recognizing EpCAM;EpCAM;Phase 1;https://ClinicalTrials.gov/show/NCT02915445
129;Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas;Recruiting;Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type|Classical Hodgkin Lymphoma|Post-transplant Lymphoproliferative Disorder;Biological: CD30.CAR-EBVST cells;CD30;Phase 1;https://ClinicalTrials.gov/show/NCT04288726
130;Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors;Recruiting;Neuroblastoma|Neuroblastoma Recurrent|GD2-positive Solid Tumors;Biological: GD2-CART01;GD2;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03373097
131;PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma;Unknown status;Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Follicular Lymphoma|Mantle Cell Lymphoma|B-cell Prolymphocytic Leukemia|Diffuse Large Cell Lymphoma;Biological: anti-CD19 CAR-NK cells;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02892695
132;A Study of CART-PSMA-TGFŒ≤RDN in Patients With Metastatic Castration Resistant Prostate Cancer;Recruiting;Metastatic Castration-resistant Prostate Cancer;Biological: CART-PSMA-TGFŒ≤RDN|Drug: Cyclophosphamide|Drug: Fludarabine;PSMA;Phase 1;https://ClinicalTrials.gov/show/NCT04227275
133;EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma;Terminated;Glioblastoma|Gliosarcoma;Biological: EGFRvIII CAR T cells;EGFRvIII;Phase 1;https://ClinicalTrials.gov/show/NCT02664363
134;Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL;Recruiting;CD19-ALL|CD19-LNH;Biological: CD19-CAR T cell;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03373071
135;Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.;Recruiting;Relapsed/Refractory Multiple Myeloma;Biological: Adult differentiated autologous T-cells with anti-BCMA specificity;BCMA;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT04309981
136;Safety and Efficacy Evaluation of IM19 Cells;Recruiting;Hematological Malignancies;Biological: IM19 CAR-T|Drug: Fludarabine|Drug: Cyclophosphamide;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03344705
137;Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL;Recruiting;Acute Lymphoblastic Leukemia|Non Hodgkin Lymphoma;Biological: Car-T Cell Therapy;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT04206943
138;PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer;Recruiting;Castration-Resistant Prostate Carcinoma|Metastatic Prostate Carcinoma|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8;Biological: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Fludarabine Phosphate;PSCA;Phase 1;https://ClinicalTrials.gov/show/NCT03873805
139;Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia;Not yet recruiting;Leukemia, B-Cell;Biological: CD19-targeted CART cells;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03599375
140;Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies;Recruiting;Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Recurrent Acute Lymphoblastic Leukemia|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage III Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Lung Non-Small Cell Cancer AJCC v7|Unresectable Lung Non-Small Cell Carcinoma;Other: Laboratory Biomarker Analysis|Biological: ROR1 CAR-specific Autologous T-Lymphocytes;ROR1;Phase 1;https://ClinicalTrials.gov/show/NCT02706392
141;Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01);Recruiting;Relapsed/Refractory Multiple Myeloma;Biological: UCARTCS1A;SLAMF7;Phase 1;https://ClinicalTrials.gov/show/NCT04142619
142;A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia;Active, not recruiting;B Cell Leukemia;Biological: Autologous CD19 CAR+ EGFTt + T cells;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT01683279
143;CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma;Recruiting;Non Hodgkin Lymphoma;Biological: CD19 CAR-T cells infusion;CD19;Not Applicable;https://ClinicalTrials.gov/show/NCT04237428
144;A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies;Recruiting;Leukemia|Lymphoma|Lymphoma, B-Cell;Biological: CAR T-Cell Infusion;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT04556266
145;Senl_1904A and Senl_1904B Chimeric Antigen Receptor ÔºàCARÔºâ T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia;Recruiting;Acute Lymphocytic Leukemia;Biological: Autologous CD19-targeting CAR T cells;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03840317
146;CD19-CAR-T2 Cells for CD19 Positive Acute Lymphoblastic Leukemia;Recruiting;Acute Lymphoblastic Leukemia, in Relapse|Acute Lymphoblastic Leukemia Not Having Achieved Remission|Acute Lymphoblastic Leukemia, Adult;Biological: CD19-CAR-T2 Cells;CD19;Phase 2;https://ClinicalTrials.gov/show/NCT04605666
147;Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma;Recruiting;Recurrent Glioblastoma|Refractory Glioblastoma;Drug: B7-H3 CAR-T|Drug: Temozolomide;B7H3;Phase 1;https://ClinicalTrials.gov/show/NCT04385173
148;Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT;Recruiting;Adult Acute Myeloid Leukemia;Biological: CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells;CD123;Phase 1;https://ClinicalTrials.gov/show/NCT03114670
150;Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies;Recruiting;Leukemia|Lymphoma;Biological: Anti-CD22-CAR-transduced T cells;CD22;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03262298
152;Study Evaluating Safety and Efficacy of UCART123 in Patients With Relapsed/ Refractory Acute Myeloid Leukemia;Recruiting;Relapsed/Refractory Acute Myeloid Leukemia;Biological: UCART123;CD123;Phase 1;https://ClinicalTrials.gov/show/NCT03190278
153;Phase I Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01);Recruiting;B-cell Acute Lymphoblastic Leukemia;Biological: UCART22;CD22;Phase 1;https://ClinicalTrials.gov/show/NCT04150497
154;Humanized CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia;Unknown status;Acute Lymphoblastic Leukemia|CD19 Positive|Relapse|Refractory;Biological: Humanized CD19 CAR-T cells|Biological: Humanized CD19 CAR-T cells with CRS suppression technology;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03275493
155;A Cancer Research UK Trial of Anti-GD2 T-cells (1RG-CART);Recruiting;Relapsed or Refractory Neuroblastoma;Genetic: 1RG-CART/m^2 (Dose Level 1)|Genetic: 1RG-CART/m^2 (Dose Level 2)|Genetic: 1RG-CART/m^2 (Dose Level 3)|Genetic: 1RG-CART/m^2 (Dose Level 4)|Drug: Cyclophosphamide|Drug: Fludarabine|Genetic: 1RG-CART/m^2 (Dose Level 5);GD2;Phase 1;https://ClinicalTrials.gov/show/NCT02761915
156;CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma;Not yet recruiting;Acute Lymphoblastic Leukemia|Burkitt Lymphoma;Biological: CD19 CAR and PD-1 knock out engineered T-cells|Biological: CD19 CAR T-cells;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03298828
157;Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM;Not yet recruiting;Multiple Myeloma in Relapse|Multiple Myeloma Progression;Biological: anti-CD19/BCMA CAR-T cells|Drug: Fludarabine|Drug: Cyclophosphamide;CD19-BCMA;Phase 1;https://ClinicalTrials.gov/show/NCT03706547
158;Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme;Unknown status;Glioblastoma Multiforme;Biological: anti-EGFRvIII CAR T cells|Drug: cyclophosphamide|Drug: Fludarabine;EGFRvIII;Phase 1;https://ClinicalTrials.gov/show/NCT02844062
159;PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies;Unknown status;Solid Tumor, Adult|Advanced Cancer;Biological: PD-1 antibody expressing Mesothelin specific CAR-T cells;Mesothelin;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03030001
160;Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*);Recruiting;Metastatic Breast Cancer;Biological: huMNC2-CAR44 CAR T cells|Biological: huMNC2-CAR44 CAR T cells @ RP2D;MUC1;Phase 1;https://ClinicalTrials.gov/show/NCT04020575
161;Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia;Withdrawn;Acute Myeloid Leukaemia;Biological: UCART123;CD123;Phase 1;https://ClinicalTrials.gov/show/NCT04106076
162;CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma;Recruiting;Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma;Procedure: CS1-CAR T Therapy|Drug: Cyclophosphamide|Drug: Fludarabine|Procedure: Leukapheresis;CS1;Phase 1;https://ClinicalTrials.gov/show/NCT03710421
163;CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML);Recruiting;Acute Myeloid Leukemia;Biological: CART-19;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03896854
164;Allogeneic CART-33 for Relapsed/Refractory CD33+ AML;Unknown status;Relapsed and/or Refractory CD33+ AML;Biological: allogeneic CART-33;CD33;Phase 1;https://ClinicalTrials.gov/show/NCT02799680
165;T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas;Recruiting;Lymphoma, Large-Cell, Anaplasitc|Enteropathy-Associated T-Cell Lymphoma|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Extranodal NK-T-Cell|Lymphoma, T-Cell, Peripheral;Biological: Anti-CD30-CAR T cells|Drug: Cyclophosphamide|Drug: Fludarabine;CD30;Phase 1;https://ClinicalTrials.gov/show/NCT03049449
166;Safety and Efficacy Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in Relapsed or Refractory Lymphoma;Recruiting;Lymphoma|Lymphoma, B-Cell|Lymphoma, Large B-Cell, Diffuse;Drug: Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy;CD19-CD22;Phase 1;https://ClinicalTrials.gov/show/NCT03593109
167;Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia;Withdrawn;Refractory B Acute Lymphoblastic Leukemia|Relapse B Acute Lymphoblastic Leukemia;Drug: Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy;CD19-CD22;Phase 1;https://ClinicalTrials.gov/show/NCT04094766
168;Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL;Unknown status;Leukemia;Biological: allogeneic CART-19;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT02799550
169;Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.;Recruiting;Solid Tumor, Adult;Biological: anti-Mesothelin CAR-T cells;Mesothelin;Phase 1;https://ClinicalTrials.gov/show/NCT03545815
170;Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia;Recruiting;ALL, Childhood B-Cell;Genetic: alloCART-19|Drug: Cyclophosphamide|Drug: Fludarabine;CD19;Early Phase 1;https://ClinicalTrials.gov/show/NCT04173988
171;C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B);Recruiting;Diffuse Intrinsic Pontine Glioma|High Grade Glioma;Genetic: (C7R)-GD2.CART cells|Drug: Cyclophosphamide|Drug: Fludarabine;GD2;Phase 1;https://ClinicalTrials.gov/show/NCT04099797
172;CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia;Recruiting;B Cell Lymphoma|B-cell Acute Lymphoblastic Leukemia;Biological: Anti-CD19 CAR-T Cells Injection;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03854994
173;JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma;Recruiting;Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma;Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014|Drug: Cyclophosphamide|Biological: Durvalumab|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT02706405
174;Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma;Active, not recruiting;B-cell Lymphoma;Biological: autologous anti-CD19 CAR T cells;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT02842138
176;Anti-Mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors;Unknown status;Mesothelin Positive Tumors;Biological: anti-Mesothelin CAR T cells;Mesothelin;Phase 1;https://ClinicalTrials.gov/show/NCT02930993
178;Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes;Unknown status;Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma;Drug: Cyclophosphamide or Bendamustine|Genetic: Dose Level -1|Genetic: Dose Level 1|Genetic: Dose Level 2|Genetic: Dose Level 3;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02134262
179;Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation;Active, not recruiting;Diffuse Large B-Cell Lymphoma;Procedure: Leukapheresis|Drug: Cyclophosphamide|Drug: Fludarabine|Biological: CAR19 T-Cells;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT02431988
180;C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N);Recruiting;Relapsed Neuroblastoma|Refractory Neuroblastoma|Relapsed Osteosarcoma|Relapsed Ewing Sarcoma|Relapsed Rhabdomyosarcoma|Uveal Melanoma|Phyllodes Breast Tumor;Genetic: C7R-GD2.CART cells|Drug: Cyclophosphamide|Drug: Fludarabine;GD2;Phase 1;https://ClinicalTrials.gov/show/NCT03635632
181;CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL;Terminated;Leukemia, Acute Lymphoblastic;Biological: CART 19;CD19;Phase 2;https://ClinicalTrials.gov/show/NCT02935543
182;CAR-T Cells in Treating Patients With Relapsed or Refractory NHL;Recruiting;Refractory Indolent Adult Non-Hodgkin Lymphoma;Drug: CD19 CAR-T|Drug: CD22 CAR-T|Drug: CD19+CD22 CAR-T|Drug: Fludarabine|Drug: Cyclophosphamide;CD19;Early Phase 1;https://ClinicalTrials.gov/show/NCT04626739
183;CD22 Redirected Autologous T Cells for ALL;Recruiting;B Cell Leukemias|B Cell Lymphomas;Biological: CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB;CD19|CD22|CD19-CD22;Phase 1;https://ClinicalTrials.gov/show/NCT02650414
184;Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma;Recruiting;Neuroblastoma;Biological: iC9.GD2.CAR.IL-15 T-cells|Drug: Cyclophosphamide|Drug: Fludarabine;GD2;Phase 1;https://ClinicalTrials.gov/show/NCT03721068
185;Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma;Active, not recruiting;Diffuse Large B Cell Lymphoma|High-grade B-cell Lymphoma|Transformed Lymphoma|Primary Mediastinal Large B Cell Lymphoma;Biological: BZ019;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT04067414
186;CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy;Unknown status;Leukemia|Lymphoma;Biological: CD19-directed CAR-T cells;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02537977
187;Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia;Not yet recruiting;B Cell Lymphoma|B-cell Acute Lymphoblastic Leukemia;Biological: Anti-CD19 CAR-T Cells Injection;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT04289220
188;Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM;Suspended;Recurrent Glioblastoma|Recurrent Gliosarcoma;Biological: EGFRvIII-CARs;EGFRvIII;Phase 1;https://ClinicalTrials.gov/show/NCT03283631
189;Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL;Recruiting;Lymphoma|Immune System Diseases|Immunoproliferative Disorders|Lymphatic Diseases|Lymphoproliferative Disorders|Neoplasms|Cutaneous Lymphoma|Cutaneous Anaplastic Large Cell Lymphoma|Mycosis Fungoides|Sezary Syndrome|Lymphomatoid Papulosis|Cutaneous T Cell Lymphoma|Gray Zone Lymphoma;Biological: ATLCAR.CD30.CCR4 cells|Biological: ALTCAR.CD30 cells|Drug: Bendamustine|Drug: Fludarabine;CD30;Phase 1;https://ClinicalTrials.gov/show/NCT03602157
191;Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma;Not yet recruiting;Recurrent Mantle Cell Lymphoma|Refractory Mantle Cell Lymphoma;Drug: Acalabrutinib|Biological: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes;CD19;Phase 2;https://ClinicalTrials.gov/show/NCT04484012
192;A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects;Completed;Refractory Diffuse Large B-Cell Lymphoma;Biological: C-CAR-011;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT02976857
193;CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor;Unknown status;Malignant Glioma of Brain|Colorectal Carcinoma|Gastric Carcinoma;Biological: anti-MUC1 CAR-T cells;MUC1;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02617134
196;Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma;Unknown status;Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Follicular Lymphoma|Mantle Cell Lymphoma|B-cell Prolymphocytic Leukemia|Diffuse Large Cell Lymphoma;Biological: PCAR-019 (anti-CD19 CAR-T cells);CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02851589
197;CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma;Unknown status;Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Follicular Lymphoma|Mantle Cell Lymphoma|B-cell Prolymphocytic Leukemia|Diffuse Large Cell Lymphoma;Biological: PCAR-019 (anti-CD19 CAR-T cells);CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02819583
198;Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML;Not yet recruiting;Relapsed/Refractory Acute Myeloid Leukemia;Drug: AMG 553;FLT3;Phase 1;https://ClinicalTrials.gov/show/NCT03904069
199;Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01;Recruiting;Neuroblastoma|Ganglioneuroblastoma;Biological: Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells)|Biological: Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells)|Biological: Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells);CD171;Phase 1;https://ClinicalTrials.gov/show/NCT02311621
200;CD4 CAR+ ZFN-modified T Cells in HIV Therapy;Active, not recruiting;Hiv;Biological: CD4 CAR+CCR5 ZFN T-cells;CD4;Phase 1;https://ClinicalTrials.gov/show/NCT03617198
201;A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE);Unknown status;Systemic Lupus Erythematosus (SLE);Drug: cyclophosphamide|Drug: anti-CD19-CAR-T cells;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03030976
202;A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia;Unknown status;Leukemia, B-Cell;Drug: anti-CD19-CAR-T cells;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02672501
203;Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL;Recruiting;Lymphoma|Lymphoma, Non-Hodgkin|Immune System Diseases|Immunoproliferative Disorders|Lymphatic Diseases|Lymphoproliferative Disorders|Neoplasms|Neoplasms by Histologic Type;Biological: ATLCAR.CD30 cells;CD30;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02690545
204;Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker;Not yet recruiting;Renal Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Prostate Cancer|Non-small Cell Lung Cancer|Breast Cancer|Colorectal Cancer;Drug: Cyclophosphamide (Non-IMP)|Drug: Fludarabine (Non-IMP)|Drug: UniCAR02-T-pPSMA|Drug: UniCAR02-T (IMP);PSMA;Phase 1;https://ClinicalTrials.gov/show/NCT04633148
205;Dose-escalating Trial With UniCAR02-T Cells and CD123 Target Module (TM123) in Patients With Hematologic and Lymphatic Malignancies;Recruiting;Acute Myeloid Leukemia (AML)|B-cell Acute Lymphoblastic Leukemia (b-ALL)|Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN);Drug: Cyclophosphamide (Non-IMP)|Drug: Fludarabine (Non-IMP)|Drug: TM123 (IMP)|Drug: UniCAR02-T (IMP);CD123;Phase 1;https://ClinicalTrials.gov/show/NCT04230265
206;CD19-redirected Autologous Cells (CAR-CD19 T Cells);Unknown status;CD19 Positive Malignant B-cell Leukemia and Lymphoma;Genetic: CAR-CD19 T cells|Drug: Fludarabine|Drug: Cyclophosphamide;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT02933775
207;iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma;Active, not recruiting;Osteosarcoma|Neuroblastoma;Genetic: GD2 T cells|Biological: VZV vaccine|Drug: Fludarabine|Drug: Cyclophosphamide;GD2;Phase 1;https://ClinicalTrials.gov/show/NCT01953900
208;Administration of T Lymphocytes for Prevention of Relapse of Lymphomas;Recruiting;Hodgkin Disease|Lymphoma|Lymphoma, Non-Hodgkin|Immune System Diseases|Immunoproliferative Disorders|Lymphatic Diseases|Lymphoproliferative Disorders|Neoplasms|Neoplasms by Histologic Type;Drug: ATLCAR.CD30 cells;CD30;Phase 1;https://ClinicalTrials.gov/show/NCT02663297
209;A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma;Recruiting;Relapsed Non Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma;Biological: CD19/22 CART|Drug: Tislelizumab;CD19-CD22;Phase 2;https://ClinicalTrials.gov/show/NCT04539444
210;Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen;Recruiting;T-cell Acute Lymphoblastic Lymphoma|T-non-Hodgkin Lymphoma|T-cell Acute Lymphoblastic Leukemia;Genetic: CD5.CAR/28zeta CAR T cells|Drug: Fludarabine|Drug: Cytoxan;CD5;Phase 1;https://ClinicalTrials.gov/show/NCT03081910
211;CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma;Completed;Hepatocellular Carcinoma;Genetic: CAR-GPC3 T cells;GPC3;Not Applicable;https://ClinicalTrials.gov/show/NCT03146234
212;Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma;Unknown status;B-cell Acute Lymphoblastic Leukemia|B-cell Lymphoma;Drug: PZ01 CAR-T cells;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03281551
213;Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma;Recruiting;Advanced Gastric Adenocarcinoma|Pancreatic Adenocarcinoma;Genetic: CAR-CLD18 T Cells;Claudin18.2;Not Applicable;https://ClinicalTrials.gov/show/NCT03159819
214;alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells;Recruiting;Unresectable Metastatic Colorectal Cancer;Drug: CYAD-101|Drug: FOLFOX|Drug: FOLFIRI;NKG2D;Phase 1;https://ClinicalTrials.gov/show/NCT03692429
215;Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma;Active, not recruiting;Refractory or Relapsed Multiple Myeloma;Genetic: CAR-BCMA T cells|Drug: Fludarabine|Drug: Cyclophosphamide;BCMA;Phase 1;https://ClinicalTrials.gov/show/NCT03716856
216;Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma;Active, not recruiting;Refractory or Relapsed Multiple Myeloma;Genetic: CAR-BCMA T cells|Drug: Fludarabine|Drug: Cyclophosphamide;BCMA;Not Applicable;https://ClinicalTrials.gov/show/NCT03380039
217;Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO);Recruiting;Non-Hodgkin's Lymphoma|B-Cell ALL|B-Cell CLL;Genetic: CD19.CAR-CD28Z T Cells - dose escalation 2|Genetic: CD19.CAR-CD28Z T Cells - dose escalation 1;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT02050347
218;CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT;Recruiting;Leukemia, Lymphocytic, Acute, B-Cell|Leukemia, Lymphocytic, Chronic, B-Cell|Lymphoma, B-Cell;Biological: CART19 cell and auto-HSCT;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03685786
219;CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM;Completed;Glioblastoma Multiforme (GBM);Biological: HER.CAR CMV-specific CTLs;HER2;Phase 1;https://ClinicalTrials.gov/show/NCT01109095
221;Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30);Active, not recruiting;Non-Hodgkin's Lymphoma|Hodgkin's Lymphoma;Drug: CAR.CD30 T cells;CD30;Phase 1;https://ClinicalTrials.gov/show/NCT01316146
222;CART-19 Immunotherapy in Mantle Cell Lymphoma;Unknown status;Hematopoietic/Lymphoid Cancer|Non-hodgkin Lymphoma,B Cell|Mantle Cell Lymphoma;Biological: anti-CD19-CAR vector-transduced T cells;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02081937
223;CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression;Recruiting;Acute Myeloid Leukemia;Biological: CAR-T CD19;CD19;Phase 2|Phase 3;https://ClinicalTrials.gov/show/NCT04257175
224;A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma;Recruiting;Multiple Myeloma;Drug: JNJ-68284528|Drug: Pomalidomide|Drug: Bortezomib|Drug: Dexamethasone|Drug: Daratumumab;BCMA;Phase 3;https://ClinicalTrials.gov/show/NCT04181827
225;BCMA-directed CAR-T Cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma;Recruiting;Multiple Myeloma;Biological: PHE885;BCMA;Phase 1;https://ClinicalTrials.gov/show/NCT04318327
226;Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies;Recruiting;B-ALL|B-cell Non Hodgkin Lymphoma|DLBCL;Drug: Fludarabine|Drug: Cyclophosphamide|Drug: CD22 CAR;CD22;Phase 1;https://ClinicalTrials.gov/show/NCT04088890
227;GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG);Recruiting;Glioma of Spinal Cord|Glioma of Brainstem;Drug: GD2 CAR T cells|Drug: Fludarabine|Drug: Cyclophosphamide;GD2;Phase 1;https://ClinicalTrials.gov/show/NCT04196413
228;CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies;Recruiting;B Cell Lymphoma|Acute Lymphoblastic Leukemia, Pediatric|Lymphoma;Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Autologous CD22 CAR T;CD22;Phase 1;https://ClinicalTrials.gov/show/NCT04088864
229;Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma;Recruiting;B-Cell Non-Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma|Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma;Drug: Acalabrutinib|Biological: Axicabtagene Ciloleucel;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT04257578
230;BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma;Unknown status;Multiple Myeloma;Biological: Anti-BCMA CAR-T cells|Drug: Fludarabine|Drug: Cyclophosphamide;BCMA;Phase 1;https://ClinicalTrials.gov/show/NCT03093168
231;BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma;Not yet recruiting;Multiple Myeloma;Biological: Anti-BCMA CAR-T cells|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Immune inhibitors;BCMA;Early Phase 1;https://ClinicalTrials.gov/show/NCT03943472
232;CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR);Recruiting;Refractory B-Cell Non-Hodgkin Lymphoma|Refractory B-Cell Small Lymphocytic Lymphoma|Relapsed Adult ALL|Relapsed CLL|Relapsed Non Hodgkin Lymphoma;Genetic: CD19.CAR-aNKT cells|Drug: Cyclophosphamide|Drug: Fludarabine;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03774654
233;CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma;Recruiting;Peripheral T Cell Lymphoma;Biological: ATLCAR.CD30 T cells|Drug: Bendamustine|Drug: Fludarabine|Drug: Cyclophosphamide;CD30;Phase 2;https://ClinicalTrials.gov/show/NCT04083495
234;BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma;Active, not recruiting;Multiple Myeloma;Biological: EGFRt/BCMA-41BBz CAR T cell|Drug: Cyclophosphamide|Drug: Lenalidomide.;BCMA;Phase 1;https://ClinicalTrials.gov/show/NCT03070327
235;XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects;Active, not recruiting;Lymphoma, B-Cell|Leukemia, B-cell;Biological: chimeric antigen receptor T cells;CD19;Phase 2;https://ClinicalTrials.gov/show/NCT03598179
236;A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma;Active, not recruiting;Leukemia;Biological: Patient-derived CD22-specific CAR T-cells also expressing an EGFRt;CD22;Phase 1;https://ClinicalTrials.gov/show/NCT03244306
237;Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies;Recruiting;B Cell Lymphoma|Acute Lymphoblastic Leukemia;Genetic: Third generation CAR-T cells;CD22;Phase 1;https://ClinicalTrials.gov/show/NCT04007978
238;CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL);Not yet recruiting;Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia;Biological: CD19-CD22 CAR-T cells;CD19-CD22;Early Phase 1;https://ClinicalTrials.gov/show/NCT04034446
239;Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome;Unknown status;Multiple Myeloma|Acute Myeloid Leukaemia|Myelodysplastic Syndrome;Biological: Anti-LeY- scFv-CD28-Œ∂ vector,.;Lewis Y;Phase 1;https://ClinicalTrials.gov/show/NCT01716364
240;A Clinical Research of CAR T Cells Targeting CEA Positive Colorectal Cancer (CRC);Not yet recruiting;Stage III Colorectal Cancer|Colorectal Cancer Liver Metastasis;Biological: Anti-CEA-CAR T;CEA;Early Phase 1;https://ClinicalTrials.gov/show/NCT04513431
241;Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T);Unknown status;AML;Drug: IM23;CD123;Phase 1;https://ClinicalTrials.gov/show/NCT03585517
242;Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma;Not yet recruiting;Lymphoma;Biological: Anti-CD19-CAR;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT04100187
243;Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia;Recruiting;CD 19+ Acute Leukemia;Biological: T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC);CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03186118
244;Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2);Recruiting;Multiple Myeloma;Biological: CT053;BCMA;Phase 1;https://ClinicalTrials.gov/show/NCT03915184
245;Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma;Recruiting;Multiple Myeloma;Biological: JCARH125|Biological: JCARH125 + anakinra;BCMA;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03430011
246;Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia;Active, not recruiting;CD19-Positive Neoplastic Cells Present|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Small Lymphocytic Lymphoma;Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes|Other: Laboratory Biomarker Analysis;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT01865617
247;Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy;Recruiting;Non-hodgkin Lymphoma,B Cell;Biological: CD19-TriCAR-T;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03720496
248;Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001);Recruiting;Non-Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma|Follicular Lymphoma|Mantle-cell Lymphoma|Primary Mediastinal B-cell Lymphoma;Biological: JCAR017 (lisocabtagene maraleucel) single-dose schedule|Biological: JCAR017 (lisocabtagene maraleucel) 2-dose schedule;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT02631044
249;Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19;Recruiting;Non-hodgkin Lymphoma,B Cell;Biological: TriCAR-T-CD19;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03497533
250;A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies;Recruiting;Relapsed or Refractory Hematological Malignancies;Biological: CNCT19;CD19;Early Phase 1;https://ClinicalTrials.gov/show/NCT04011293
251;T-Cell Therapy for Advanced Breast Cancer;Recruiting;Breast Cancer|Metastatic HER2-negative Breast;Drug: Cyclophosphamide|Biological: Mesothelin-targeted T cells|Drug: AP1903;Mesothelin;Phase 1;https://ClinicalTrials.gov/show/NCT02792114
252;Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies;Recruiting;B-Lymphoid Malignancies|Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Non-hodgkin Lymphoma;Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Mesna|Biological: iC9/CAR.19/IL15-Transduced CB-NK Cells|Drug: AP1903;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03056339
253;CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients;Withdrawn;Glioma of Brain|CAR-T Cell Immunotherapy;Biological: GD2 CAR-T immunotherapy;GD2;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT04406610
254;B7-H3 CAR-T for Recurrent or Refractory Glioblastoma;Recruiting;Recurrent Glioblastoma|Refractory Glioblastoma;Drug: Temozolomide|Biological: B7-H3 CAR-T;B7H3;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT04077866
255;Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET);Terminated;Malignant Melanoma|Breast Cancer;Biological: T cells modified with RNA anti -cMET CAR;cMET;Early Phase 1;https://ClinicalTrials.gov/show/NCT03060356
256;CD19 Redirected Autologous T Cells for Hodgkin Lymphoma;Terminated;Hodgkin Lymphoma With no Available Curative Treatment Options Who Have a Limited Prognosis;Biological: RNA anti-CD19 CAR T cells;CD19;Early Phase 1;https://ClinicalTrials.gov/show/NCT02277522
257;Study Evaluating the Efficacy and Safety With CAR-T for Liver Cancer;Unknown status;Liver Neoplasms;Biological: EpCAM-targeted CAR-T cells;EpCAM;Not Applicable;https://ClinicalTrials.gov/show/NCT02729493
258;Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer;Unknown status;Stomach Neoplasms;Biological: EpCAM-targeted CAR-T cells;EpCAM;Not Applicable;https://ClinicalTrials.gov/show/NCT02725125
259;Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia;Active, not recruiting;Leukemia;Biological: CD19-targeted CAR-T cells;CD19;Not Applicable;https://ClinicalTrials.gov/show/NCT02735291
260;Quikin CD19-CART in Patients With r/r B-cell Lymphoma;Recruiting;B-cell Lymphoma;Biological: CD19-Specific Chimeric Antigen Receptor T cells with PD1 knockout;CD19;Not Applicable;https://ClinicalTrials.gov/show/NCT04213469
262;CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma;Active, not recruiting;Primary Mediastinal B-cell Lymphoma|Diffuse, Large B-cell Lymphoma|Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma|Mantle Cell;Drug: Fludarabine|Drug: Cyclophosphamide|Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL|Drug: Aldesleukin;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT00924326
263;Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma;Unknown status;Lymphoma;Biological: CD19-targeted CAR-T cells;CD19;Not Applicable;https://ClinicalTrials.gov/show/NCT02728882
264;CAR19 Donor Lymphocytes for Relapsed CD19+ Malignancies Following Allogeneic Transplantation;Active, not recruiting;CD19+ Malignancies: Relapse Post-allogeneic Transplant;Genetic: Infusion of modified CAR19 T-cells (4G7-CARD T-cells);CD19;Phase 1;https://ClinicalTrials.gov/show/NCT02893189
265;Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL;Not yet recruiting;Leukemia|Lymphoma;Biological: :Anti-CD22-CAR;CD22;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT04163575
267;Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138;Unknown status;Multiple Myeloma;Biological: CART-138 cells;CD138;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT01886976
268;Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T);Completed;Leukemia;Biological: IM19 CAR-T|Drug: fludarabine and cyclophosphamide;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03173417
269;Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL;Unknown status;Leukemia|Lymphoma;Biological: Anti-CD19-CAR;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT02546739
270;Immunotherapy With CD19 CAR Œ≥Œ¥T-cells for B-Cell Lymphoma, ALL and CLL;Unknown status;Leukemia|Lymphoma;Biological: Anti-CD19-CAR Œ≥Œ¥T;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT02656147
271;Intervention of CAR-T Against Cervical Cancer;Recruiting;Cervical Cancer;Biological: Cervical cancer-specific CAR-T cells;GD2|PSMA|Muc1|Mesothelin;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03356795
272;Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma;Active, not recruiting;Multiple Myeloma;Biological: bb2121;BCMA;Phase 2;https://ClinicalTrials.gov/show/NCT03361748
273;CART-meso in Mesothelin Expressing Cancers;Completed;Metastatic Pancreatic (Ductal) Adenocarcinoma|Epithelial Ovarian Cancer|Malignant Epithelial Pleural Mesothelioma;Biological: CART-meso;Mesothelin;Phase 1;https://ClinicalTrials.gov/show/NCT02159716
274;CAR-T for R/R B-NHL;Recruiting;Relapsed Non Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|CAR - T CD19/CD20/CD22/CD30;Biological: CAR-T;CD19-CD20-CD22-CD30;Phase 2;https://ClinicalTrials.gov/show/NCT03196830
275;CAR T Cell Immunotherapy for Pancreatic Cancer;Active, not recruiting;Pancreatic Cancer|Cancer of the Pancreas;Biological: huCART-meso cells;Mesothelin;Phase 1;https://ClinicalTrials.gov/show/NCT03323944
276;CAR T Cells in Mesothelin Expressing Cancers;Recruiting;Lung Adenocarcinoma|Ovarian Cancer|Peritoneal Carcinoma|Fallopian Tube Cancer|Mesotheliomas Pleural|Mesothelioma Peritoneum;Biological: huCART-meso cells;Mesothelin;Phase 1;https://ClinicalTrials.gov/show/NCT03054298
277;A Single-Center, Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer;Recruiting;Epithelial Ovarian Cancer;Biological: LCAR-M23 cells;Mesothelin;Phase 1;https://ClinicalTrials.gov/show/NCT04562298
278;Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma;Unknown status;Recurrent or Refractory B Cell Malignancy;Biological: Mixed CD19/CD20 CAR-T Transfer;CD19-CD20;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03207178
279;Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer;Recruiting;Pancreatic Cancer;Biological: CART-meso cells;Mesothelin;Not Applicable;https://ClinicalTrials.gov/show/NCT03638193
280;Tisagenlecleucel In Primary CNS Lymphoma;Recruiting;Primary CNS Lymphoma|Refractory Primary CNS Lymphoma|Relapsed Primary CNS Lymphoma;Biological: Tisagenlecleucel;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT04134117
281;Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma;Recruiting;Large B-cell Lymphoma;Biological: BZ019;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT04250324
282;A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma;Recruiting;Relapsed or Refractory Multiple Myeloma;Biological: C-CAR088;BCMA;Phase 1;https://ClinicalTrials.gov/show/NCT03815383
283;A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma;Recruiting;Relapsed or Refractory Multiple Myeloma;Biological: C-CAR088;BCMA;Phase 1;https://ClinicalTrials.gov/show/NCT03751293
284;A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma;Recruiting;Advanced Hepatocellular Carcinoma;Biological: CD147-CART;CD147;Phase 1;https://ClinicalTrials.gov/show/NCT03993743
285;CD147-CART Cells in Patients With Recurrent Malignant Glioma.;Recruiting;Recurrent Glioblastoma|CD147 Positive;Biological: CD147-CART;CD147;Early Phase 1;https://ClinicalTrials.gov/show/NCT04045847
286;Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T;Not yet recruiting;Relapsed/Refractory B-cell Lymphomas|Diffuse Large B-Cell Lymphoma (DLBCL)|Follicular Lymphoma (FL)|Chronic Lymphocytic Leukemia (CLL)|Marginal Zone Lymphoma (MZL)|Mantle Cell Lymphoma (MCL)|Small Lymphocytic Lymphoma (SLL)|Primary Mediastinal Large B Cell Lymphoma|Transformed Follicular Lymphoma;Combination Product: CLBR001 and SWI019;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT04488354
287;Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma;Recruiting;Multiple Myeloma in Relapse;Biological: Treatment;BCMA|CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03767725
288;LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma;Active, not recruiting;Refractory or Relapsed Multiple Myeloma;Biological: LCAR-B38M CAR-T cell injection;BCMA;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03090659
289;Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy;Recruiting;CD7+ Acute Leukemia|CD7+ Lymphoma;Biological: anti-CD7 CAR-T;CD7;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT04599556
290;A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM;Not yet recruiting;Multiple Myeloma;Biological: BCMA/CD19 dual-target CAR-T cell immunotherapy;BCMA-CD19;Early Phase 1;https://ClinicalTrials.gov/show/NCT04412889
291;Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia;Completed;Patients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options;Biological: CART-19;CD19;Phase 2;https://ClinicalTrials.gov/show/NCT02030847
292;A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL;Unknown status;Refractory or Relapsed B-cell Non-Hodgkin Lymphoma;Biological: C-CAR011;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03299738
293;Treatment of Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden;Recruiting;Refractory or Relapsed Non-Hodgkin's Lymphoma;Drug: Chidamide|Drug: Decitabine|Drug: Chidamide and Decitabine|Biological: Tandem CAR19/20 engineered T cells;CD19-CD20;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT04553393
294;A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma;Recruiting;Multiple Myeloma;Biological: BCMA/CD19 Dual-Target CAR-T;BCMA-CD19;Early Phase 1;https://ClinicalTrials.gov/show/NCT04182581
295;Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL;Recruiting;Acute Lymphoid Leukemia;Biological: huCART19;CD19;Phase 2;https://ClinicalTrials.gov/show/NCT03792633
296;Phase 2 Trial of CD19 Redirected Autologous T Cells;Recruiting;"Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL|Infants With Very High Risk KMT2A B-ALL|Patients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation";Biological: Murine CART19;CD19;Phase 2;https://ClinicalTrials.gov/show/NCT04276870
297;A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors;Active, not recruiting;Solid Tumor|Soft Tissue Sarcoma|Gastric Cancer|Pancreatic Cancer|Bladder Cancer;Biological: CCT301-59;ROR2;Phase 1;https://ClinicalTrials.gov/show/NCT03960060
298;Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors;Recruiting;Pancreatic Adenocarcinoma|Gastric Adenocarcinoma|Prostate Adenocarcinoma;Biological: BPX-601|Drug: Rimiducid;PSCA;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02744287
299;Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC;Unknown status;Primary Hepatocellular Carcinoma;Biological: c-Met/PD-L1 CAR-T cell injection;cMET;Early Phase 1;https://ClinicalTrials.gov/show/NCT03672305
300;Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer;Terminated;Pancreatic Cancer;Biological: CART-meso-19 T cells|Drug: Cyclophosphamide;Mesothelin|CD19;Phase 1;https://ClinicalTrials.gov/show/NCT02465983
302;Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma;Recruiting;Clinical Stage IV Cutaneous Melanoma AJCC v8|IL13RA2 Positive|Metastatic Melanoma|Cutaneous Melanoma, Stage III|Cutaneous Melanoma, Stage IV;Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Biological: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells|Drug: Recombinant Interleukin-2;IL13Ralpha2;Phase 1;https://ClinicalTrials.gov/show/NCT04119024
303;CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia;Recruiting;Childhood Acute Lymphoblastic Leukemia;Drug: CD19 CAR-T|Drug: CD22 CAR-T|Drug: CD 19+22|Drug: Fludarabine|Drug: Cyclophosphamide;CD19|CD22|CD19-CD22;Early Phase 1;https://ClinicalTrials.gov/show/NCT04626765
304;Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies;Recruiting;B Cell Malignancy;Biological: ThisCART19 cells;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT04384393
305;Efficacy and Safety Evaluation of BCMA-UCART;Recruiting;Multiple Myeloma;Biological: BCMA-UCART;BCMA;Not Applicable;https://ClinicalTrials.gov/show/NCT03752541
306;Combination Transfer of Œ±CD19-TCRz-41BB and Œ±CD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy;Unknown status;Hematopoietic/Lymphoid Cancer;Biological: Mixed CAR-T Transfer;CD19|CD22;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02903810
307;The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).;Unknown status;B-cell Acute Lymphoblastic Leukemia;Drug: Cyclophosphamide|Drug: Fludarabine|Biological: CART-19 cells;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT02924753
308;Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients;Recruiting;NHL;Drug: IM19 CAR-T Cells;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT04440436
309;CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma;Recruiting;Relapsed or Refractory Multiple Myeloma;Drug: BCMA CAR-T|Drug: Fludarabine|Drug: Cyclophosphamide;BCMA;Early Phase 1;https://ClinicalTrials.gov/show/NCT04626752
310;A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors;Recruiting;Solid Tumor|Gastric Cancer|Breast Cancer|Ovarian Cancer|Sarcoma;Biological: CCT303-406;HER2;Phase 1;https://ClinicalTrials.gov/show/NCT04511871
311;A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma;Unknown status;Pancreatic Cancer;Drug: TAI-meso-CART;Mesothelin;Phase 1;https://ClinicalTrials.gov/show/NCT02706782
312;CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA);Not yet recruiting;Non-hodgkin Lymphoma|Acute Lymphoblastic Leukemia;Biological: CD19.CAR-multiVST for Group A|Biological: CD19.CAR-multiVST for Group B;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03768310
313;A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART);Unknown status;Carcinoma, Hepatocellular;Drug: GPC3-CART cells;GPC3;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03130712
314;"A Trial of ""Armored"" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies";Recruiting;Chronic Lymphocytic Leukemia (CLL)|Relapsed|Refractory;Biological: EGFRt/19-28z/4-1BBL CAR T cells;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03085173
315;Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma;Unknown status;Lung Squamous Cell Carcinoma;Genetic: CAR-GPC3 T Cells|Drug: Fludarabine|Drug: Cyclophosphamide;GPC3;Phase 1;https://ClinicalTrials.gov/show/NCT02876978
316;Safety and Efficacy Evaluation of CD19-UCART;Recruiting;Acute Lymphoblastic Leukemia (ALL)|Non Hodgkin Lymphoma (NHL);Biological: CD19-UCART;CD19;Not Applicable;https://ClinicalTrials.gov/show/NCT03229876
317;A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Malignancies Who Have Been Previously Administered With UCART19;Enrolling by invitation;Advanced Lymphoid Malignancies;Biological: UCART19 follow-up;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT02735083
318;Competitive Transfer of Œ±CD19-TCRz-CD28 and Œ±CD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma;Unknown status;Hematopoietic/Lymphoid Cancer|Adult Acute Lymphoblastic Leukemia in Remission|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma;Biological: anti-CD19 CAR-T|Drug: Fludarabine|Drug: Cyclophosphamide;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02685670
319;Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma;Recruiting;B-cell Adult Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Hematopoietic/Lymphoid Cancer|Refractory Chronic Lymphocytic Leukemia;Biological: anti-CD19 CAR-T|Drug: Fludarabine|Drug: Cyclophosphamide;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03110640
321;Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma;Recruiting;Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma;Biological: Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143|Drug: Cyclophosphamide|Drug: Fludarabine|Other: Laboratory Biomarker Analysis|Procedure: Leukapheresis;BCMA;Phase 1;https://ClinicalTrials.gov/show/NCT03338972
322;A Study of GPC3 Redirected Autologous T Cells for Advanced HCC;Unknown status;Carcinoma, Hepatocellular;Drug: TAI-GPC3-CART cells;GPC3;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02715362
323;LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer;Recruiting;Castrate-Resistant Prostate Cancer;Biological: LIGHT-PSMA-CART cells;PSMA;Phase 1;https://ClinicalTrials.gov/show/NCT04053062
325;A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer;Recruiting;Colon Cancer|Esophageal Carcinoma|Pancreatic Cancer|Prostate Cancer|Gastric Cancer|Hepatic Carcinoma;Biological: CAR-T cell immunotherapy;EpCAM;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03013712
326;CART-19 Post-ASCT for Multiple Myeloma;Terminated;Multiple Myeloma;Biological: CART-19 cells;CD19;Phase 2;https://ClinicalTrials.gov/show/NCT02794246
327;Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies;Recruiting;Acute Lymphoblastic Leukemia|B Cell Lymphoma;Genetic: Second generation CAR-T cells|Procedure: Hematological stem cell transplantation;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03366324
328;A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART);Unknown status;Liver Metastases;Biological: MG7-CART;MG7;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02862704
330;Study on GD2 Positive Solid Tumors by 4SCAR-GD2;Recruiting;Solid Tumor;Genetic: 4SCAR-GD2;GD2;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02992210
331;Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies;Recruiting;Acute Lymphoblastic Leukemia|B Cell Lymphoma;Procedure: Allogeneic hematological stem cell transplantation;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03366350
332;Zeushield Cytotoxic T Lymphocytes (Z-CTLs) for Relapsed or Refractory Non Small Cell Lung Cancer (NSCLC);Unknown status;Non-small Cell Lung Cancer;Biological: Zeushield Cytotoxic T Lymphocytes;PDL1|CD80;Early Phase 1;https://ClinicalTrials.gov/show/NCT03060343
333;Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN);Recruiting;Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Acute Lymphocytic Leukemia;Biological: CD19 CAR T Cells|Drug: Fludarabine|Drug: Cyclophosphamide;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT01853631
334;CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies;Recruiting;Acute Lymphoblastic Leukemia|Non-Hodgkin's Lymphoma;Biological: CLIC-1901;Cd19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03765177
335;Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma;Active, not recruiting;Renal Cell Carcinoma;Biological: CCT301-38|Biological: CCT301-59;ROR2|Axl;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03393936
336;huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia;Recruiting;Adult B Acute Lymphoblastic Leukemia|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Adult Acute Lymphoblastic Leukemia|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Recurrent Transformed Non-Hodgkin Lymphoma|Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements;Biological: Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes|Drug: Cyclophosphamide|Drug: Fludarabine|Other: Laboratory Biomarker Analysis|Procedure: Leukapheresis|Other: Pharmacological Study;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03103971
337;CART22 Alone or in Combination With huCART19 for ALL;Recruiting;Chemotherapy Resistant Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia;Biological: CART22-65s cells|Biological: huCART19 Cells;CD22;Phase 1;https://ClinicalTrials.gov/show/NCT03620058
338;Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients;Recruiting;Multiple Myeloma;Drug: clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells;BCMA;Phase 3;https://ClinicalTrials.gov/show/NCT04287660
339;Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL;Recruiting;Lymphoma|Myeloma|Leukemia;Biological: Kappa CD28 T cells;Kappa;Phase 1;https://ClinicalTrials.gov/show/NCT00881920
340;Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL;Not yet recruiting;B-ALL;Drug: CD19/CD22 CAR-T;CD19-CD22;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT04499573
341;Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm;Recruiting;Adult Acute Myeloid Leukemia in Remission|Acute Biphenotypic Leukemia|Early Relapse of Acute Myeloid Leukemia|Late Relapse of Acute Myeloid Leukemia|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Blastic Plasmacytoid Dendritic Cell Neoplasm|Acute Myeloid Leukemia|Adult Acute Lymphoblastic Leukemia|Interleukin-3 Receptor Subunit Alpha Positive|Minimal Residual Disease|Refractory Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia;Drug: cyclophosphamide|Biological: Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes|Other: laboratory biomarker analysis|Biological: Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes|Drug: Fludarabine Phosphate;CD123;Phase 1;https://ClinicalTrials.gov/show/NCT02159495
342;CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma;Recruiting;Diffuse Large B-cell Lymphoma;Biological: CD19-7√ó19 CAR-T plus PD1 monoclonal antibody;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT04381741
343;Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia;Completed;B-cell Acute Lymphoblastic Leukemia;Biological: UCART19;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT02746952
344;Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma;Completed;Neuroblastoma;Biological: GD2 CAR modified Tri-virus specific cytotoxic t-cells;GD2;Phase 1;https://ClinicalTrials.gov/show/NCT01460901
345;A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Gastric Cancer;Recruiting;Gastric Cancer;Biological: LCAR-C18S cells;Claudin18.2;Phase 1;https://ClinicalTrials.gov/show/NCT04467853
346;A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma;Terminated;Gastric Cancer|Pancreatic Ductal Adenocarcinoma;Biological: LCAR-C182A cells;Claudin18.2;Early Phase 1;https://ClinicalTrials.gov/show/NCT03890198
347;CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor;Unknown status;Advanced Solid Tumor;Biological: Anti-CTLA-4/PD-1 expressing MUC1-CAR-T;MUC1;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03179007
348;CTLA-4 and PD-1 Antibodies Expressing Mesothelin-CAR-T Cells for Mesothelin Positive Advanced Solid Tumor;Unknown status;Advanced Solid Tumor;Biological: CTLA-4/PD-1 antibodies expressing mesoCAR-T;Mesothelin;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03182803
349;CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor;Unknown status;Advanced Solid Tumor;Biological: anti-CTLA-4/PD-1 expressing EGFR-CAR-T;EGFR;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03182816
350;Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33;Unknown status;Relapsed Adult Myeloid Leukemia|Chemotherapy Refractory Adult Myeloid Leukemia;Biological: CART33 cells|Biological: anti-CD33 CART|Biological: anti-CD33 CAR T cells;CD33;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT01864902
351;CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma;Withdrawn;CD19 Positive|Mantle Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma;Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Carmustine|Drug: Cytarabine|Drug: Etoposide|Biological: Filgrastim|Drug: Melphalan|Biological: Rituximab|Biological: Umbilical Cord Blood-derived Natural Killer Cells;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03579927
352;Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia;Recruiting;Lymphoblastic Leukemia, Acute Adult;Biological: TBI-1501;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03155191
354;Phase I Trial: T4 Immunotherapy of Head and Neck Cancer;Recruiting;Head and Neck Cancer;Other: Intra-tumoral T4 immunotherapy;ErbB;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT01818323
355;Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies;Recruiting;Follicular Lymphoma|ALL|NHL|Large Cell Lymphoma;Biological: CD22-CAR;CD22;Phase 1;https://ClinicalTrials.gov/show/NCT02315612
356;CAR-37 T Cells In Hematologic Malignancies;Recruiting;Hematologic Malignancy|Leukemia|Lymphoma|Lymphoma, B-Cell|Lymphoma, T-Cell|Lymphoma, Non-Hodgkin;Biological: CAR-37 T cells;CD37;Phase 1;https://ClinicalTrials.gov/show/NCT04136275
357;Humanized CAR-T Therapy for Treatment of B Cell Malignancy;Unknown status;Leukemia, Lymphocytic, Chronic, B-Cell;Biological: CAR-T;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02782351
358;Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL);Terminated;Acute Lymphoblastic Leukemia;Biological: JCAR015 (CD19-targeted CAR T cells);CD19;Phase 2;https://ClinicalTrials.gov/show/NCT02535364
359;A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma;Recruiting;Multiple Myeloma;Drug: SLAMF7 CAR-T;SLAMF7;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT04499339
360;CAR T Cells for Refractory B Cell Malignancy;Recruiting;B-Cell Leukemia|B-Cell Lymphoma;Biological: Autologous CD19-targeting CAR T cells;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02963038
361;A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma;Recruiting;B Cell Leukemia|B Cell Lymphoma;Biological: UCART019;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03166878
362;Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia;Recruiting;Acute Lymphoblastic Leukemia, in Relapse|Acute Lymphoblastic Leukemia, Refractory;Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Mesna|Device: CliniMACS|Biological: CD19- specific CAR engineered autologous T-cells (SJCAR19 product);CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03573700
363;A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia;Recruiting;CD19+ Acute Leukemia;Biological: Patient Derived CD19 specific CAR T cells also expressing an EGFRt;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02028455
364;An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection;Recruiting;Diffuse Large B Cell Lymphoma;Biological: Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells;CD19-CD20;Phase 1;https://ClinicalTrials.gov/show/NCT04486872
366;CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy;Active, not recruiting;B-cell Leukemia|B-Cell Lymphoma;Biological: CAR T cells;CD19;Phase 2;https://ClinicalTrials.gov/show/NCT03068416
367;CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia;Unknown status;B-cell Acute Lymphocytic Leukemia;Biological: CD19 CAR-T cells;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03064269
368;Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL;Recruiting;CD19-positive ALL;Biological: anti-CD19/CD22 CAR-T cells|Drug: Fludarabine|Drug: Cyclophosphamide;CD19-CD22;Phase 1;https://ClinicalTrials.gov/show/NCT04303520
369;Safety and Efficacy Evaluation of IM19 CAR-T Cells;Unknown status;Leukemia;Biological: IM19 CAR-T;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03142646
370;The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer;Recruiting;Ovarian Cancer;Drug: anti- MESO CAR-T cells|Drug: Fludarabine|Drug: Cyclophosphamide;Mesothelin;Early Phase 1;https://ClinicalTrials.gov/show/NCT03814447
371;A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies;Unknown status;Myeloid Malignancies;Biological: Anti-LeY-CAR-transduced T cells;Lewis Y;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02958384
372;Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES;Recruiting;POMES Syndrome|Relapsed and Refractory POMES Syndrome;Biological: anti-CD19/BCMA CAR-T cells|Drug: Fludarabine|Drug: Cyclophosphamide;BCMA-CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03879382
373;A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies;Recruiting;Myeloid Malignancies;Biological: Anti-CD33-CAR-transduced T cells;CD33;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02958397
374;The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma;Unknown status;B Cell Lymphoma;Drug: Cyclophosphamide|Drug: Fludarabine|Biological: CART-19;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03101709
375;Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC);Unknown status;Hepatocellular Carcinoma;Biological: Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs|Drug: Fludarabine|Drug: Cyclophosphamide;GPC3;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03084380
376;A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies;Recruiting;Leukemia;Biological: Anti-CD123-CAR-transduced T cells;CD123;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02937103
377;Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL;Unknown status;Leukemia|Lymphoma;Biological: anti-CD19 anti-CD20 Bispecific CAR-T;CD19-CD20;Phase 1;https://ClinicalTrials.gov/show/NCT03271515
378;A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies;Recruiting;Leukemia|Lymphoma;Biological: Anti-CD20-CAR-transduced T cells;CD20;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02710149
379;Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies;Recruiting;Adult T-Cell Lymphoma/Leukaemia|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|NK/T-cell Lymphoma|Peripheral T Cell Lymphoma|Hodgkin Lymphoma;Genetic: Anti-CD30 CAR T cells;CD30;Phase 1;https://ClinicalTrials.gov/show/NCT04008394
380;A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies;Recruiting;Leukemia|Lymphoma|Multiple Myeloma;Biological: Anti-BCMA-CAR-transduced T cells;BCMA;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02954445
381;Anti-ALPP CAR-T Cells Immunotherapy for Ovarian and Endometrial Cancer;Not yet recruiting;Ovarian Cancer|Endometrial Cancer;Drug: Retroviral vector-transduced autologous T cells to express anti-ALPP CARs;ALPP;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT04627740
382;A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies;Recruiting;Leukemia|Lymphoma;Biological: Anti-CD30-CAR-transduced T cells;CD30;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02958410
383;Descartes-11 in Multiple Myeloma;Recruiting;Multiple Myeloma;Biological: Descartes-11|Drug: Fludarabine|Drug: Cyclophosphamide;BCMA;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03994705
385;CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies;Recruiting;B-cell Malignancy|B-cell Lymphoma|B-Cell Acute Lymphoblastic Leukaemia;Biological: CD19 CAR T;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03559439
386;EGFR-IL12-CART Cells for Patients With Metastatic Colorectal Cancer;Not yet recruiting;Metastatic Colorectal Cancer;Biological: EGFR IL12 CART;EGFR;Phase 1;https://ClinicalTrials.gov/show/NCT03542799
387;Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation;Recruiting;Adult B Acute Lymphoblastic Leukemia;Drug: CD19 CAR-T|Drug: CD22 CAR-T|Drug: CD19+CD22 CAR-T|Drug: Fludarabine|Drug: Cyclophosphamide;CD19|CD22|CD19-CD22;Early Phase 1;https://ClinicalTrials.gov/show/NCT04626726
388;EGFR CART Cells for Patients With Metastatic Colorectal Cancer;Unknown status;EGFR-positive Colorectal Cancer;Biological: EGFR CART;EGFR;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03152435
389;Study of AIC100 in Relapsed/Refractory Thyroid Cancer;Recruiting;Anaplastic Thyroid Cancer|Relapsed/Refractory Poorly Differentiated Thyroid Cancer;Biological: AIC100 CAR T Cells;ICAM1;Phase 1;https://ClinicalTrials.gov/show/NCT04420754
390;A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL);Recruiting;Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia;Biological: AUTO1;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT04404660
391;A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies;Recruiting;Leukemia|Lymphoma;Biological: Anti-CD22-CAR-transduced T cells;CD22;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02935153
392;Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia;Unknown status;Acute Leukemia;Biological: CD19-CAR-T2 Cells;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT02822326
393;CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.;Unknown status;B Cell Lymphoma;Drug: Fludarabine|Drug: Cyclophosphamide|Biological: CD19 CART;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03146533
394;CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL;Recruiting;B-cell Acute Lymphoblastic Leukemia|Acute Lymphocytic Leukemia, Pediatric;Biological: Chimeric Antigen Receptor T-Cell Therapy|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Tocilizumab;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03467256
395;the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL);Unknown status;Lymphoma, Large B-Cell, Diffuse;Biological: Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells;CD19|CD20;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02737085
396;Œ±PD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors;Recruiting;Colorectal Cancer|Ovarian Cancer;Biological: Œ±PD1-MSLN-CAR T cells;Mesothelin;Early Phase 1;https://ClinicalTrials.gov/show/NCT04503980
397;Œ±PD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors;Recruiting;Non-small-cell Lung Cancer|Mesothelioma;Biological: Œ±PD1-MSLN-CAR T cells;Mesothelin;Early Phase 1;https://ClinicalTrials.gov/show/NCT04489862
398;Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-cell Lymphoma;Recruiting;Relapsed or Refractory DLBCL Patients With Either CD19 or CD20 Positive;Biological: Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells;CD19-CD20;Phase 1;https://ClinicalTrials.gov/show/NCT04215016
399;CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies;Active, not recruiting;Acute Lymphoblastic Leukemia|Burkitt Lymphoma;Procedure: Leukapheresis|Drug: Lymphodepletion with fludarabine|Drug: Lymphodepletion with cyclophosphamide|Biological: CD19 CAR T-cells;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT02443831
400;Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor;Unknown status;Hepatocellular Carcinoma|Non-small Cell Lung Cancer|Pancreatic Carcinoma|Triple-Negative Invasive Breast Carcinoma;Biological: anti-MUC1 CAR T Cells;MUC1;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02587689
401;Anti-GPC3 CAR T for Treating Patients With Advanced HCC;Completed;Hepatocellular Carcinoma;Biological: anti-GPC3 CAR T;GPC3;Phase 1;https://ClinicalTrials.gov/show/NCT02395250
402;CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR;Unknown status;Advanced Glioma;Biological: anti-EGFR CAR T;EGFR;Phase 1;https://ClinicalTrials.gov/show/NCT02331693
403;Lentivirally Redirected CD123 Autologous T Cells in AML;Recruiting;Acute Myeloid Leukemia, in Relapse|Acute Myeloid Leukemia, Adult|Acute Myeloid Leukemia, Refractory;"Biological: CART123 cells; cyclophosphamide; fludarabine";CD123;Phase 1;https://ClinicalTrials.gov/show/NCT03766126
404;CD19-CAR-T Cells in Patients With R/R B-ALL;Unknown status;B-cell Acute Lymphoblastic Leukemia;Biological: CD19-CAR-T Cells;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03574168
405;CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies;Recruiting;Non Hodgkin Lymphoma (NHL)|Mantle Cell Lymphoma (MCL);Biological: 8-Day Production of Car-T Cells|Biological: 12-Day Production of Car-T Cells;CD19-CD20;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT04186520
406;Study of PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning of PC in Mesothelin Positive Multiple Solid Tumors;Unknown status;Solid Tumor, Adult;Biological: Mesothelin-directed CAR-T cells;Mesothelin;Phase 1;https://ClinicalTrials.gov/show/NCT03747965
407;CD123 Redirected Autologous T Cells for AML;Terminated;Relapsed or Refractory Acute Myeloid Leukemia;Biological: Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes|Drug: Cyclophosphamide;CD123;Early Phase 1;https://ClinicalTrials.gov/show/NCT02623582
408;A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia;Unknown status;B Acute Lymphoblastic Leukemia;Genetic: prophylactic 4SCAR19 cells;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT02968472
409;Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia;Recruiting;Acute Myelocytic Leukemia;Biological: CD123 CAR-T cells;CD123;Phase 1;https://ClinicalTrials.gov/show/NCT03796390
410;CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies;Recruiting;Leukemia|Lymphoma;Biological: Autologous CAR-T;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03121625
411;CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies;Recruiting;Leukemia|Lymphoma|Multiple Myeloma of Bone (Diagnosis);Biological: Autologous CAR-T cells;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03312205
413;CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies;Unknown status;Recurrent or Refractory B Cell Malignancy;Biological: CD22 CAR-T;CD22;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02794961
416;A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies;Recruiting;Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Lymphoma;Combination Product: Drugs and anti-CD19 CAR transduced T cells;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03191773
417;Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma;Active, not recruiting;Relapsed/Refractory Multiple Myeloma;Genetic: KITE-585|Drug: Cyclophosphamide|Drug: Fludarabine;BCMA;Phase 1;https://ClinicalTrials.gov/show/NCT03318861
418;CD19-specific CAR-T Cells in CLL/SLL and DLBCL;Recruiting;"Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Diffuse Large B-cell Lymphoma; Acute Lymphoblastic Leukemia";Drug: YTB323 and ibrutinib|Drug: YTB323 single agent;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03960840
419;Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma;Terminated;Hodgkin Lymphoma;Biological: CD19 RNA redirected autologous T-cells (RNA CART19 cells);CD19;Early Phase 1;https://ClinicalTrials.gov/show/NCT02624258
420;Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer;Recruiting;Platinum-Resistant Fallopian Tube Carcinoma|Platinum-Resistant Ovarian Carcinoma|Platinum-Resistant Primary Peritoneal Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Refractory Fallopian Tube Carcinoma|Refractory Ovarian Carcinoma|Refractory Primary Peritoneal Carcinoma|Stage III Fallopian Tube Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Primary Peritoneal Cancer AJCC v8|Stage IIIA Fallopian Tube Cancer AJCC v8|Stage IIIA Ovarian Cancer AJCC v8|Stage IIIA Primary Peritoneal Cancer AJCC v8|Stage IIIA1 Fallopian Tube Cancer AJCC v8|Stage IIIA1 Ovarian Cancer AJCC v8|Stage IIIA2 Fallopian Tube Cancer AJCC v8|Stage IIIA2 Ovarian Cancer AJCC v8|Stage IIIB Fallopian Tube Cancer AJCC v8|Stage IIIB Ovarian Cancer AJCC v8|Stage IIIB Primary Peritoneal Cancer AJCC v8|Stage IIIC Fallopian Tube Cancer AJCC v8|Stage IIIC Ovarian Cancer AJCC v8|Stage IIIC Primary Peritoneal Cancer AJCC v8|Stage IV Fallopian Tube Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Primary Peritoneal Cancer AJCC v8|Stage IVA Fallopian Tube Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Primary Peritoneal Cancer AJCC v8|Stage IVB Fallopian Tube Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Primary Peritoneal Cancer AJCC v8;Biological: PRGN-3005 UltraCAR-T cells;MUC16;Phase 1;https://ClinicalTrials.gov/show/NCT03907527
422;Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma;Unknown status;Lymphoma, B-Cell;Biological: CART20;CD20;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02965157
423;A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer;Withdrawn;Breast Cancer|Ovarian Cancer|Lung Cancer|Gastric Cancer|Colorectal Cancer|Glioma|Pancreatic Cancer;Biological: Anti-HER2 CAR-T;HER2;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02713984
424;Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma;Recruiting;Relapsed and Refractory Multiple Myeloma;Drug: CART-ddBCMA;BCMA;Phase 1;https://ClinicalTrials.gov/show/NCT04155749
426;A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies;Recruiting;B-cell Malignancies;Genetic: Therapeutic 4SCAR19 cells;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03050190
427;CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.;Completed;B Cell Lymphoma|B Cell Leukemia;Biological: Autologous 3rd generation CD19-targeting CAR T cells;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02132624
428;4SCAR-T Therapy Post CD19-targeted Immunotherapy;Recruiting;CD19 Negative B-cell Malignancies;Biological: Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20;CD22|CD123|CD38|CD10|CD20;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT04430530
430;CAR-T Immunotherapy Targeting CD19- ALL;Recruiting;B-cell Leukemia;Biological: 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR;CD22|CD123|CD38|CD10|CD20|TSLPR;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT04016129
431;Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy;Not yet recruiting;B-Cell Non-Hodgkin Lymphoma;Biological: Anakinra|Biological: Axicabtagene Ciloleucel;CD19;Phase 2;https://ClinicalTrials.gov/show/NCT04359784
432;Combination CAR-T Cell Therapy Targeting Hematological Malignancies;Recruiting;B-cell Malignancies;Biological: 4SCAR19 and 4SCAR22|Biological: 4SCAR19 and 4SCAR38|Biological: 4SCAR19 and 4SCAR20|Biological: 4SCAR19 and 4SCAR123|Biological: 4SCAR19 and 4SCAR70|Biological: 4SCAR19 and 4SCAR30;CD20|CD22|CD30|CD38|CD70|CD123;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03125577
433;CART-BCMA Cells for Multiple Myeloma;Completed;Multiple Myeloma;Biological: CART-BCMA;BCMA;Phase 1;https://ClinicalTrials.gov/show/NCT02546167
434;Multi-CAR-T Cells Targeting B Cell Lymphomas;Recruiting;B Cell Lymphoma (BCL);Biological: 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2;CD20|CD22|CD70|PSMA|CD79B|GD2;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT04429438
435;Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas;Completed;Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas;Biological: CART-19;CD19;Phase 2;https://ClinicalTrials.gov/show/NCT02030834
437;Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma;Completed;Myeloma, Plasma-Cell|Myeloma-Multiple;Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells;BCMA;Phase 1;https://ClinicalTrials.gov/show/NCT02215967
440;An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma;Recruiting;Multiple Myeloma;Biological: bb2121;BCMA;Phase 2;https://ClinicalTrials.gov/show/NCT03601078
441;Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas;Unknown status;B-cell Lymphomas;Genetic: Anti-CD19 CAR T cells;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02247609
442;Axi-cel in CNS Lymphoma;Not yet recruiting;Lymphoma|Lymphoma Cns;Drug: Fludarabine|Drug: Cyclophosphamide|Biological: Axicabtagene Ciloleucel;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT04608487
445;Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies;Not yet recruiting;B-cell Acute Lymphoblastic Leukemia|B-cell Lymphoma;Biological: anti-CD19 UCAR-T cells|Drug: Fludarabine|Drug: Cytoxan|Drug: Melphalan;CD19;Early Phase 1;https://ClinicalTrials.gov/show/NCT04264039
446;Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies;Not yet recruiting;T-cell Leukemia|T-cell Lymphoma;Biological: CD7 UCAR-T cells|Drug: Fludarabine|Drug: Cytoxan|Drug: Melphalan;CD7;Early Phase 1;https://ClinicalTrials.gov/show/NCT04264078
447;Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma;Unknown status;Lymphoma;Biological: Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy;CD19-CD22;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03468153
448;Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276;Recruiting;Solid Tumor;Biological: 4SCAR-276;B7H3;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT04432649
449;A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma;Recruiting;Leukemia|Lymphoma;Biological: SCRI-CAR22v2;CD22;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT04571138
450;CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273);Unknown status;Lymphomas;Genetic: Anti-CD30 CAR T cells;CD30;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02274584
451;A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia;Recruiting;Leukemia|Lymphoma;Biological: Patient-derived CD19- and CD22 specific CAR;CD19|CD22;Phase 1;https://ClinicalTrials.gov/show/NCT03330691
452;CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma;Recruiting;Leukemia|Lymphoma;Biological: SCRI-huCAR19v1|Biological: SCRI-huCAR19v2;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03684889
453;Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma;Recruiting;Lymphoma, Non-Hodgkin;Drug: JCAR017;CD19;Phase 2;https://ClinicalTrials.gov/show/NCT03484702
455;Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients;Unknown status;Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Stage III/IV Adult Diffuse Large Cell Lymphoma|Stage III/IV Follicular Lymphoma|Stage III/IV Mantle Cell Lymphoma;Drug: Retroviral vector-transduced autologous T cells to express CD22-specific CARs;CD22;Phase 1;https://ClinicalTrials.gov/show/NCT02721407
456;Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma;Unknown status;Relapsed or Refractory B-cell Lymphoma;Biological: iPD1 CD19 eCAR T cells|Drug: Fludarabine and cyclophosphamide;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03208556
457;TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL);Recruiting;B Acute Lymphoblastic Leukemia;Drug: PBLTT52CAR19;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT04557436
458;B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults;Recruiting;Pediatric Solid Tumor|Germ Cell Tumor|Retinoblastoma|Hepatoblastoma|Wilms Tumor|Rhabdoid Tumor|Carcinoma|Osteosarcoma|Ewing Sarcoma|Rhabdomyosarcoma|Synovial Sarcoma|Clear Cell Sarcoma|Malignant Peripheral Nerve Sheath Tumors|Desmoplastic Small Round Cell Tumor|Soft Tissue Sarcoma|Neuroblastoma|Melanoma;Biological: second generation 4-1BBŒ∂ B7H3-EGFRt-DHFR|Biological: second generation 4-1BBŒ∂ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBŒ∂ CD19-Her2tG;B7H3-CD19;Phase 1;https://ClinicalTrials.gov/show/NCT04483778
459;Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma;Unknown status;Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Follicular Lymphoma|Stage IV Mantle Cell Lymphoma;Drug: CD19.CAR-T cells;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02652910
461;Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors;Not yet recruiting;Bladder Cancer|Head and Neck Squamous Cell Carcinoma|Cancer of the Salivary Gland|Lung Cancer|Breast Cancer|Gastric Cancer|Esophageal Cancer|Colorectal Cancer|Pancreatic Adenocarcinoma|Solid Tumor;Biological: CAdVEC;HER2;Phase 1;https://ClinicalTrials.gov/show/NCT03740256
462;EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults;Recruiting;Pediatric Solid Tumor|Germ Cell Tumor|Retinoblastoma|Hepatoblastoma|Wilms Tumor|Rhabdoid Tumor|Carcinoma|Osteosarcoma|Ewing Sarcoma|Rhabdomyosarcoma|Synovial Sarcoma|Clear Cell Sarcoma|Malignant Peripheral Nerve Sheath Tumors|Desmoplastic Small Round Cell Tumor|Soft Tissue Sarcoma|Neuroblastoma;Biological: second generation 4-1BBŒ∂ EGFR806-EGFRt|Biological: second generation 4-1BBŒ∂ EGFR806-EGFRt and a second generation 4 1BBŒ∂ CD19-Her2tG;EGFR;Phase 1;https://ClinicalTrials.gov/show/NCT03618381
467;Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma;Completed;Malignant Pleural Mesothelioma;Genetic: Adoptive Transfer of re-directed T cells;FAP;Early Phase 1;https://ClinicalTrials.gov/show/NCT01722149
470;Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1);Recruiting;Multiple Myeloma;Biological: CAR-BCMA T Cells;BCMA;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03975907
471;Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma;Recruiting;Multiple Myeloma|Immune System Diseases;Drug: CAR138 T Cells;CD138;Phase 1;https://ClinicalTrials.gov/show/NCT03672318
472;Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma;Recruiting;Lymphoma|Lymphoma, B-Cell|Immune System Diseases|Immunoproliferative Disorders|Lymphatic Diseases;Biological: iC9-CAR19 T cells|Drug: Bendamustine|Drug: Fludarabine|Drug: AP1903|Drug: Cyclophosphamide;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03696784
473;Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma;Completed;B Cell Leukemia|B Cell Lymphoma;Biological: CART-19;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT01626495
474;Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma;Recruiting;Relapsed/Refractory Large B-cell Lymphoma;Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Lenzilumab|Biological: Axicabtagene Ciloleucel;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT04314843
476;MB-CART19.1 in Patients With R/R ALL;Unknown status;Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory;Drug: MB-CART19.1;CD19;Phase 2;https://ClinicalTrials.gov/show/NCT03321123
477;Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL;Recruiting;Acute Lymphoblastic Leukemia|Immune System Diseases|Immunoproliferative Disorders;Biological: iC9-CAR19 cells|Drug: Rimiducid|Drug: Cyclophosphamide|Drug: Fludarabine;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03016377
478;Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20;Withdrawn;Neuromyelitis Optica Spectrum Disorder;Biological: Corticosteroids & tanCART19/20;CD19-CD20;Phase 1;https://ClinicalTrials.gov/show/NCT03605238
479;Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies;Recruiting;Esophagus Cancer|Hepatoma|Glioma|Gastric Cancer;Biological: CAR-T/TCR-T cells immunotherapy;EGFRvIII|Mesothelin;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03941626
480;Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT;Recruiting;Acute Lymphoblastic Leukemia, in Relapse;Biological: CARCIK-CD19;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03389035
481;MB-CART20.1 Melanoma;Recruiting;Melanoma (Skin);Biological: MB-CART20.1;CD20;Early Phase 1;https://ClinicalTrials.gov/show/NCT03893019
482;Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies;Recruiting;B-cell Acute Lymphoblastic Leukemia|Lymphoma|Myeloid Leukemia|Multiple Myeloma|Hepatoma|Gastric Cancer|Pancreatic Cancer|Mesothelioma|Colorectal Cancer|Esophagus Cancer|Lung Cancer|Glioma|Melanoma|Synovial Sarcoma|Ovarian Cancer|Renal Carcinoma;Biological: CAR-T cell immunotherapy;CD19|CD22|CD33|BCMA|CD38|DR5|cMET|EGFRvIII|Mesothelin;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03638206
484;MB-CART20.1 Lymphoma;Recruiting;Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|B-cell Lymphoma Refractory|B-cell Lymphoma Recurrent;Biological: MB-CART20.1;CD20;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03664635
485;MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM);Recruiting;Acute Lymphoblastic Leukemia Recurrent|B-cell Lymphoma Recurrent|B-cell Lymphoma Refractory|Chronic Lymphocytic Leukemia Recurrent|Chronic Lymphocytic Leukemia Refractory;Biological: MB-CART19.1;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03853616
486;Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma;Active, not recruiting;Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma;Procedure: peripheral blood stem cell transplantation (PBSCT)|Biological: filgrastim|Genetic: polymerase chain reaction|Biological: rituximab|Biological: genetically engineered lymphocyte therapy|Other: laboratory biomarker analysis|Drug: plerixafor|Procedure: autologous hematopoietic stem cell transplantation;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT01318317
487;Retreatment With CTL019/CTL119;Not yet recruiting;Lymphoma, B-Cell;Drug: CD19 redirected autologous T cells (CTL019 or CTL119 cells);CD19;Phase 1;https://ClinicalTrials.gov/show/NCT04419909
488;Study of bb21217 in Multiple Myeloma;Active, not recruiting;Multiple Myeloma;Biological: bb21217;BCMA;Phase 1;https://ClinicalTrials.gov/show/NCT03274219
489;CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell ALL;Completed;B Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Refractory Childhood Acute Lymphoblastic Leukemia|B-cell Acute Lymphoblastic Leukemia;Biological: AUTO3 (CD19/22 CAR T cells;CD19-CD22;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03289455
490;CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma;Recruiting;Diffuse Large B Cell Lymphoma|Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|DLBCL;Biological: AUTO3;CD19-CD22;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03287817
491;Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma;Recruiting;Acute Lymphoblastic Leukemia|Relapsed Non Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma;Biological: Brexucabtagene Autoleucel (KTE-X19)|Drug: Fludarabine|Drug: Cyclophosphamide;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02625480
492;Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma;Recruiting;Refractory B-Cell Non-Hodgkin Lymphoma|Relapsed B-cell Non-Hodgkin Lymphoma;Biological: CAR-CD19 T Cells;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03994913
493;BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma;Unknown status;Relapsed and Refractory Multiple Myeloma;Biological: BCMA CAR-T Cells;BCMA;Early Phase 1;https://ClinicalTrials.gov/show/NCT03661554
494;A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma;Recruiting;Multiple Myeloma;Drug: C-CAR088;BCMA;Phase 1;https://ClinicalTrials.gov/show/NCT04295018
495;Study to Evaluate the Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma;Active, not recruiting;Relapsed/Refractory Mantle Cell Lymphoma;Biological: brexucabtagene autoleucel|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Axicabtagene Ciloleucel;CD19;Phase 2;https://ClinicalTrials.gov/show/NCT02601313
496;Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL);Active, not recruiting;Refractory Diffuse Large B Cell Lymphoma;Biological: KTE-C19|Biological: Atezolizumab|Drug: Cyclophosphamide|Drug: Fludarabine;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02926833
497;Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma;Recruiting;Multiple Myeloma|Multiple Myeloma in Relapse|Neoplasm, Plasma Cell;Biological: BCMA CAR-T cells;BCMA;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT04272151
498;BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma;Recruiting;Multiple Myeloma|Neoplasm, Plasma Cell|Multiple Myeloma in Relapse;Biological: BCMA CAR-T cells;BCMA;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT04271644
499;Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells;Not yet recruiting;T-cell Acute Lymphoblastic Leukemia|T-cell Acute Lymphoblastic Lymphoma|T-non-Hodgkin Lymphoma;Genetic: CD7.CAR/28zeta CAR T cells|Drug: Fludarabine|Drug: Cytoxan;CD7;Phase 1;https://ClinicalTrials.gov/show/NCT03690011
500;A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma;Recruiting;Multiple Myeloma;Drug: C-CAR088;BCMA;Phase 1;https://ClinicalTrials.gov/show/NCT04322292
501;Her2 and TGFBeta Cytotoxic T Cells in Treatment of Her2 Positive Malignancy;Completed;HER2 Positive Malignancies;Biological: TGFBeta resistant HER2/EBV-CTLs;HER2;Phase 1;https://ClinicalTrials.gov/show/NCT00889954
503;Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies;Unknown status;B-Cell Malignancies;Biological: Low dose ET019002- T Cells|Biological: Middle dose ET019002- T Cells|Biological: High dose ET019002- T Cells;CD19;Early Phase 1;https://ClinicalTrials.gov/show/NCT03642496
504;P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC);Recruiting;Prostatic Neoplasms, Castration-Resistant|Neoplasms by Histologic Type|Neoplasms, Prostate|Prostate Cancer|Metastatic Castration-resistant Prostate Cancer|Neoplasms|Prostatic Neoplasms|Genital Neoplasms, Male|Urogenital Neoplasms|Neoplasms by Site|Prostatic Disease;Biological: P-PSMA-101 CAR-T cells|Drug: Rimiducid;PSMA;Phase 1;https://ClinicalTrials.gov/show/NCT04249947
505;4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma;Recruiting;Neuroblastoma;Biological: GD2, PSMA and CD276 CAR-T cells;GD2|PSMA|B7H3;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT04637503
506;T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma;Recruiting;Myeloma-Multiple|Myeloma, Plasma-Cell;Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Rimiducid|Biological: Anti-SLAMF7 CAR T cells;SLAMF7;Phase 1;https://ClinicalTrials.gov/show/NCT03958656
507;Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors;Recruiting;Solid Tumor, Adult|Cervical Cancer|Sarcoma|NSCLC;Biological: Autologous aPD-L1 armored anti-CD22 CAR T cells;CD22;Phase 1;https://ClinicalTrials.gov/show/NCT04556669
508;T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma;Recruiting;Myeloma-Multiple|Myeloma, Plasma-Cell;Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Anti-BCMA CAR T cells;BCMA;Phase 1;https://ClinicalTrials.gov/show/NCT03602612
509;In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies;Recruiting;Acute Lymphocytic Leukemia|Lymphoma;Biological: Biological/Genetically Modified T cells|Drug: Cyclophosphamide-based chemotherapy;BCMA;Phase 1;https://ClinicalTrials.gov/show/NCT01430390
510;P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM);Recruiting;Multiple Myeloma;Biological: P-BCMA-101 CAR-T cells|Drug: Rimiducid;BCMA;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03288493
511;CD19-Specific T Cells Post AlloSCT;Recruiting;"B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent Mantle Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Ph-Like Acute Lymphoblastic Leukemia|Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory B Acute Lymphoblastic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Refractory Mantle Cell Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Ph-Like Acute Lymphoblastic Leukemia|Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Small Lymphocytic Lymphoma";Biological: Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells|Drug: Cyclophosphamide|Drug: Fludarabine;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03579888
512;Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART);Recruiting;Neoplasm, Stomach|Metastases, Neoplasm|Neoplasm Seeding;Biological: CAR-T cells targeting EpCAM|Biological: Chemotherapy;EpCAM;Phase 1;https://ClinicalTrials.gov/show/NCT03563326
517;Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma;Active, not recruiting;B-cell Lymphoma;Biological: Axicabtagene Ciloleucel|Drug: Fludarabine|Drug: Cyclophosphamide;CD19;Phase 2;https://ClinicalTrials.gov/show/NCT03761056
518;Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma;Recruiting;Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma;Biological: brexucabtagene autoleucel (KTE-X19)|Drug: Fludarabine|Drug: Cyclophosphamide;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03624036
520;A Study of TAK-102 in Adult Patients With GPC3-Expressing Previously Treated Solid Tumors;Recruiting;Solid Tumors;Biological: TAK-102;GPC3;Phase 1;https://ClinicalTrials.gov/show/NCT04405778
521;Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma;Active, not recruiting;Refractory Diffuse Large B Cell Lymphoma (DLBCL)|Relapsed Diffuse Large B-Cell Lymphoma|Transformed Follicular Lymphoma (TFL)|Primary Mediastinal B-cell Lymphoma (PMBCL)|High Grade B-cell Lymphoma (HGBCL);Biological: Axicabtagene Ciloleucel|Drug: Fludarabine|Drug: Cyclophosphamide;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02348216
522;Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma;Recruiting;Lymphoma, B-Cell;Biological: CD19-PD1-CART Cell;CD19;Phase 2;https://ClinicalTrials.gov/show/NCT04163302
523;BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma;Recruiting;Multiple Myeloma;Biological: GC012F injection;BCMA-CD19;Early Phase 1;https://ClinicalTrials.gov/show/NCT04236011
524;T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia;Active, not recruiting;Relapsed B-Cell Acute Lymphoblastic Leukemia;Procedure: leukapheresis or collection of PBMCs|Drug: cyclophosphamide based chemotherapy regimens|Biological: modified T cells;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT01860937
525;Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma;Active, not recruiting;Refractory Large B-cell Lymphoma;Biological: Axicabtagene Ciloleucel|Drug: Rituximab|Drug: Fludarabine|Drug: Cyclophosphamide;CD19;Phase 2;https://ClinicalTrials.gov/show/NCT04002401
526;Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma;Recruiting;Relapsed/Refractory Large B-cell Lymphoma;Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Axicabtagene Ciloleucel|Biological: Utomilumab;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03704298
527;Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma;Active, not recruiting;Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL);Biological: Axicabtagene Ciloleucel|Drug: Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.|Drug: Cyclophosphamide|Drug: Fludarabine;CD19;Phase 3;https://ClinicalTrials.gov/show/NCT03391466
529;Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma;Recruiting;Multiple Myeloma;Biological: BCMA-PD1-CART Cell;BCMA;Phase 2;https://ClinicalTrials.gov/show/NCT04162119
530;Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN, AML, and hrMDS.;Recruiting;Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)|Acute Myeloid Leukemia|Relapsed or Refractory HRMDS;Biological: MB-102|Drug: Decitabine|Drug: Fludarabine|Drug: Cyclophosphamide;CD123;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT04109482
531;Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma;Recruiting;Multiple Myeloma;Biological: CAR T cells;BCMA-CD38-CD56-CD138;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03271632
532;CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30);Recruiting;Hodgkin's Lymphoma|Non-Hodgkin Lymphoma;Genetic: CAR T Cells|Drug: Cyclophosphamide|Drug: Fludarabine;CD30;Phase 1;https://ClinicalTrials.gov/show/NCT02917083
533;PSMA-specific CAR-T Cell Therapy;Recruiting;PSMA Positive Tumors or Tumor Tissues;Biological: 4SCAR-PSMA T cells;PSMA;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT04429451
534;BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma;Not yet recruiting;Multiple Myeloma;Biological: GC012F injection;BCMA-CD19;Early Phase 1;https://ClinicalTrials.gov/show/NCT04617704
535;Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma;Recruiting;Mantle Cell Lymphoma Recurrent;Combination Product: ibrutinib and Tisagenlecleucel;CD19;Phase 2;https://ClinicalTrials.gov/show/NCT04234061
536;Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma;Recruiting;Glioblastoma|Malignant Glioma|Recurrent Glioma|Refractory Glioma|WHO Grade III Glioma;Biological: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes|Biological: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Other: Laboratory Biomarker Analysis|Procedure: Leukapheresis;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT03389230
537;Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL);Recruiting;Leukemia, Lymphocytic, Chronic, B-Cell|Lymphoma, Small Lymphocytic;Biological: JCAR017 (lisocabtagene maraleucel)|Biological: JCAR017 (lisocabtagene maraleucel) + ibrutinib;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03331198
538;Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006);Recruiting;Lymphoma, Non-Hodgkin|Lymphoma, Nonhodgkin|Lymphoma, B-Cell|Lymphoma, Large B-Cell, Diffuse;Biological: lisocabtagene maraleucel;CD19;Phase 2;https://ClinicalTrials.gov/show/NCT03483103
539;A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007);Recruiting;Lymphoma, Non-Hodgkin|Lymphoma|Lymphoma, B-Cell|Lymphoma, Large B-Cell, Diffuse|Neoplasms|Neoplasms by Histologic Type|Lymphoproliferative Disorders|Lymphatic Diseases|Immunoproliferative Disorders|Immune System Disorder;Biological: lisocabtagene maraleucel;CD19;Phase 2;https://ClinicalTrials.gov/show/NCT03744676
540;A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM);Recruiting;Lymphoma, Non-Hodgkin|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Follicular;Biological: JCAR017|Drug: Durvalumab|Drug: CC-122|Drug: Ibrutinib|Drug: CC-220;CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03310619
542;Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma;Active, not recruiting;Follicular Lymphoma;Biological: tisagenlecleucel;CD19;Phase 2;https://ClinicalTrials.gov/show/NCT03568461
543;Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients;Active, not recruiting;Diffuse Large B-cell Lymphoma (DLBCL);Biological: CTL019;CD19;Phase 2;https://ClinicalTrials.gov/show/NCT02445248
545;Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma;Recruiting;Recurrent Glioblastoma|Recurrent Malignant Glioma|Recurrent WHO Grade II Glioma|Recurrent WHO Grade III Glioma|Refractory Glioblastoma|Refractory Malignant Glioma|Refractory WHO Grade II Glioma|Refractory WHO Grade III Glioma;Biological: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells|Biological: IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes|Other: Laboratory Biomarker Analysis|Procedure: Magnetic Resonance Imaging|Procedure: Magnetic Resonance Spectroscopic Imaging|Other: Quality-of-Life Assessment;IL13Ralpha2;Phase 1;https://ClinicalTrials.gov/show/NCT02208362
548;Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Recruiting;Multiple Myeloma;Biological: bb2121|Drug: Daratumumab|Drug: Pomalidomide|Drug: Dexamethasone|Drug: Bortezomib|Drug: Ixazomib|Drug: Lenalidomide|Drug: Carfilzomib|Drug: Elotuzumab;BCMA;Phase 3;https://ClinicalTrials.gov/show/NCT03651128
549;Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial;Not yet recruiting;Recurrent Neuroblastoma|Recurrent Osteosarcoma|Refractory Neuroblastoma|Refractory Osteosarcoma;Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Biological: GD2-CAR-expressing Autologous T-lymphocytes;GD2;Phase 1;https://ClinicalTrials.gov/show/NCT04539366
551;Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso;Unknown status;Malignant Mesothelioma|Pancreatic Cancer|Ovarian Tumor|Triple Negative Breast Cancer|Endometrial Cancer|Other Mesothelin Positive Tumors;Biological: anti-meso-CAR vector transduced T cells;Mesothelin;Phase 1;https://ClinicalTrials.gov/show/NCT02580747
552;Treatment of Chemotherapy Refractory Human Epidermalgrowth Factor Receptor-2( HER-2) Positive Advanced Solid Tumors;Unknown status;Advanced HER-2 Positive Solid Tumors|Chemotherapy Refactory|HER-2 Antibody Inhibitor Therapy Refactory;Biological: CART-HER-2;HER2;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT01935843
553;Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR);Unknown status;Advanced EGFR-positive Solid Tumors;Biological: CART-EGFR;EGFR;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT01869166
554;Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133;Completed;Liver Cancer|Pancreatic Cancer|Brain Tumor|Breast Cancer|Ovarian Tumor|Colorectal Cancer|Acute Myeloid and Lymphoid Leukemias;Biological: anti-CD133-CAR vector-transduced T cells;CD133;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT02541370
559;Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma;Recruiting;Multiple Myeloma;Biological: CART-138/BCMA/19/more;CD138|BCMA|CD19;Phase 1|Phase 2;https://ClinicalTrials.gov/show/NCT03196414
560;Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC);Active, not recruiting;Prostate Cancer;Biological: engineered autologous T cells|Drug: cyclophosphamide;PSMA;Phase 1;https://ClinicalTrials.gov/show/NCT01140373
563;A Phase I Study of CD19 Specific T Cells in CD19 Positive Malignancy;Unknown status;CD19 Positive Non-Hodgkin Lymphoma;Genetic: aCD19z cells, IL2, pre conditioning Cyclophosphamide & Fludarabine;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT01493453
564;Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19;Active, not recruiting;Leukemia|Acute Lymphoblastic Leukemia;Biological: gene-modified T cells targeted;CD19;Phase 1;https://ClinicalTrials.gov/show/NCT01044069